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ABSTRACT 
Nef is an accessory protein encoded by human and simian immunodeficiency viruses 
(HIV and SIV), and is critical for viral pathogenicity in vivo. The structure of Nef has 
been resolved and the major cellular activities of Nef are generally described as down-
regulation of cell surface molecules, enhancement of virus infectivity and regulation of 
cell signaling and activation. Macrophages represent a key target of HIV-1 infection and 
may contribute significantly to viral pathogenesis by facilitating viral propagation, 
maintaining a viral reservoir and regulating viral replication. During HIV-1 infection, 
various cytokines and chemokines are induced for viral advantages more than for host 
defense.   
We have previously demonstrated that HIV-1 Nef regulates the release of chemokines, 
MIP-1α and MIP-1β, from infected macrophages and have proposed that this may 
enhance conditions for viral replication by promoting recruitment of substrate 
lymphocytes to sites of infection (1). However, the molecular basis for this Nef activity 
remains to be defined. The main goals of this thesis are to identify the functional motif in 
Nef that is responsible for chemokine induction in macrophages and to elucidate the 
relevance of this motif to other Nef functions. Using a mutagenesis approach, we have 
eventually identified a novel motif (KEK) that regulates chemokine production in 
infected macrophages after we excluded several previously described Nef motifs. This 
motif is conserved in both HIV-1 and SIV Nef proteins. Mutations in this domain 
abrogated MIP-1β induction as well as the Nef-dependent release of other secretory 
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factors by macrophages. However, disruption of this motif did not affect other Nef-
ascribed activities such as CD4 and MHC-I down-regulation. In addition, we have 
determined the involvement of viral Env proteins in Nef-induced chemokine production. 
Distinct signaling pathways that regulate chemokine release in macrophage will also be 
described. Finally, several possible roles of the KEK motif are proposed and some 
preliminary results of co-immunoprecipitation experiments will be presented which aim 
to characterize cellular proteins involved in chemokine regulation by Nef. Collectively, 
our studies reveal a specific determinant within Nef that is critical for chemokine release 
by Nef. Identification of this motif paves the way for future studies to explore the 
molecular machanisms of Nef-regulated cell signaling pathways. Such knowledge may 
point to new therapeutic strategies that interrupt Nef function and limit the course of 
HIV-1 infection.      
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INTRODUCTION 
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1. HIV-1 and SIV 
1.1. Primate lentivirus and AIDS 
The lentivirus Human immunodeficiency virus type 1 (HIV-1) was first identified in 
1983 when Luc Montagnier’s group at the Pasteur Institute isolated a novel retrovirus 
named lymphadenopathy-associated virus (LAV) (2). Robert Gallo’s group at NIH also 
identified the virus and named it as human T-cell leukemia virus III (HTLV-III). They 
confirmed that this was the pathogen that caused acquired immunodeficiency syndrome 
(AIDS) in humans (3).  Two years later, simian T-cell leukemia virus III (STLV-III), now 
referred to as simian immunodeficiency virus (SIV), was isolated from rhesus macaques 
with an AIDS-like illness and this virus presented similar morphology, growth pattern 
and antigenic properties as HTLV-III, providing the first evidence of the close 
relationship between SIV and HIV (4) . It is now widely believed that SIV from African 
primates may have crossed species from monkeys to humans resulting in different HIV 
strains. HIV-1 may have originated from the evolution of SIVcpz, an SIV strain from 
infected chimpanzees (5, 6), while the less pathogenic HIV-2 appears to be a relative of 
SIVsm, an SIV strain from infected sooty mangabeys (7),(8).  
HIVand its relative SIV are primate lentiviruses belonging to the retroviridae family.  
The “retro-” in the family name emphasizes a unique step in replication of these RNA 
viruses: synthesis of viral DNA from an RNA genome by reverse transcriptase, while the 
“lenti-” in the genus name stands for a slow incubation time usually followed by a latent 
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but eventually destructive infection. Since the first five AIDS patients were reported in 
1981, HIV infection has killed approximately 30 million people. According to a 2009 
UNAIDS report, about 33.4 million people are living with HIV infection.  Most untreated 
HIV-1 infected people will develop AIDS and die from opportunistic infections or tumors 
due to the total failure of the immune system. Unfortunately, there is currently no cure for 
HIV infection, although a cocktail therapy with combined usage of at least three 
antiretroviral drugs, referred to as highly active antiretroviral therapy (HAART), has 
successfully controlled HIV infection and reduced AIDS mortality by suppressing viral 
replication. This therapy, however, has to be continuous since it is unable to completely 
clear a latent viral reservoir from the host. This makes the treatment expensive. For this 
reason, the majority of HIV infected people in developing countries are still short of 
proper treatment and medication. An affordable vaccine, considered to be the ultimate 
solution, has not been developed. In September 2009, a combination of two previously 
failed vaccine candidates was reported to reduce HIV infection by 30% according to a 
vaccine trail in Thailand (9). The news is encouraging but it is still far from a preventive 
vaccine, especially considering the numbers of the infected people in the vaccine and the 
placebo groups were actually very close (51 vs.74) making the significance of the results 
questionable. In addition to the development of novel drugs and vaccines, restoration of 
the impaired immune system of HIV patients using bone marrow or stem cell transplant 
may offer another option to finally cure AIDS in the future (10). 
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1.2. HIV-1 genome and viral proteins 
The HIV-1 genome, depending on the stage of the viral replication cycle, may be present 
in RNA or DNA form. In a typical viral particle, the viral genome appears as two copies 
of single-stranded RNAs whereas in an intracellular pre-integration complex (PIC) it 
becomes double-stranded DNA after reverse transcription. On both ends of the genome 
are two identical sequences termed as 5’- and 3’- long terminal repeats (LTRs) and 
between them there are 9 open reading frames (ORF) (Fig. 1-1). The gag, pol and env are 
the three fundamental genes common to all retroviruses, and in HIV-1 they initially 
encode polyprotein precursors that are processed into individual viral proteins. According 
to their distinct functions, the viral proteins of HIV-1 can be categorized into four groups: 
the structural proteins encoded by gag and env, the enzymatic proteins encoded by pol, 
the regulatory proteins Tat and Rev, and the accessory proteins Vif, Vpu, Vpr and Nef.  
These viral proteins exhibit a multitude of activities that can act in concert and contribute 
to the pathogenicity of HIV-1. The functions of each viral protein have been reviewed in 
detail (11). 
The gag gene encodes a polyprotein precursor p55 that is cleaved by viral protease into 
matrix (MA/p17), capsid (CA/p24), nucleocapsid (NC/p7) and P6, along with two 
additional spacer peptides, p1 and p2. The MA domain of the p55 directs Gag to the 
cellular membrane after its synthesis (12) and also facilitates the incorporation of the Env 
proteins into virions (13). The structural function of CA protein is to form the viral core 
(14) but it also affects viral infectivity, probably through its association with  
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Figure 1-1: Genomic organization of HIV-1. LTRs are shown as grey boxes and ORFs 
as blank boxes.  
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cyclophilin A (CypA) during the viral uncoating step (15, 16). NC specifically binds to 
the packaging signal (-site) of the unspliced genomic RNA and directs them into 
virions (17). P6 promotes virus release by interacting with Tsg101 (18, 19) and P6 also 
facilitates the incorporation of the accessory protein Vpr into virus particles (20) . 
The env gene encodes viral envelope (Env) as a glycoprotein precursor gp160 that is 
cleaved by a cellular protease into the surface unit (SU) gp120 and the transmembrane 
domain (TM) gp41.  The spike unit gp120 interacts with its receptor CD4 and co-
receptors CXCR4 or CCR5 on target cells and thus determines viral tropism. The 
transmembrane unit gp41 binds to gp120, stabilizes the gp120/gp41 complex and 
mediates fusion between viral and host lipid membranes during virus entry (21). 
A frameshift event during Gag translation leads to the synthesis of three pol gene 
products, protease (PR), reverse transcriptase (RT) and integrase (IN), as part of a large 
Gag-Pol precursor. The first substrate of PR is likely to be itself so that it can be released 
and continue with the subsequent processing of the Gag and Gag-Pol precursors, which is 
required for virion maturation. RT generates the double-stranded DNA copy from the 
single-stranded RNA viral genome in infected cells. It has both RNA- and DNA-
dependent polymerase activities and its RNase H domain removes the RNA template 
from the RNA/DNA hybrid during double-stranded DNA synthesis. As an error prone 
polymerase, RT causes a high mutation rate during viral replication (22), which is an 
efficient way for HIV-1 to evade antibodies and antiviral drugs. After reverse 
transcription, IN catalyzes the integration of viral DNA into the host genome. This 
 
 
7 
 
includes at least 3 steps, 3’ processing of the viral DNA, strand transfer and gap repair, 
which lead to the formation of the integrated provirus. 
Tat and Rev are two regulatory proteins that enhance viral gene expression. Tat interacts 
with the transactivation response (TAR) element in the 5’-LTR and functions to stimulate 
the LTR-directed transcriptional elongation by recruiting a cyclin T1/CDK9 complex to 
hypophosphorylate the C-terminal domain (CTD) of RNA polymerase II (23, 24). Rev 
serves as a nuclear exporter for unspliced genomic viral RNA or partially spliced viral 
mRNAs by binding to the Rev-responsive element (RRE) (25, 26). Tat and Rev are 
indispensable for a complete viral replication cycle because the efficient expression of 
most viral proteins is largely dependent on them. 
The HIV-1 genome encodes an additional four proteins, viral infectivity factor (Vif), viral 
protein u (Vpu), viral protein r (Vpr) and negative factor (Nef). These are collectively 
termed “accessory” proteins due to the fact that their absence usually has little effect on 
viral replication in cell cultures. However, recent studies have revealed that they carry 
important activities that support viral replication. Vif enhances virus infectivity by 
countering the antiviral effect of APOBEC3G (27). Vpu is reported to overcome another 
cellular restriction factor tetherin/BST-2 that prevents virus release (28) and it also down-
regulates intracellular CD4 expression (29), which helps to avoid envelope interference. 
Vpr enhances viral replication in nondividing macrophages (30) possibly by facilitating 
nuclear import of the HIV-1 PIC (31, 32) and it is also known to induce cell cycle arrest 
in G2 phase (33, 34).  My thesis research is mainly focused on the accessory protein Nef, 
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which is probably the most multifunctional viral protein of HIV-1.  Studies dealing with 
Nef structure and activities will be reviewed in detail in the Chapter I-2. 
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1.3. HIV-1 replication cycle 
Productive HIV-1 infection requires that virions go through a complete HIV-1 replication 
cycle which includes the following critical steps: receptor/co-receptor binding, membrane 
fusion, virion uncoating, reverse transcription, PIC nuclear import, viral DNA integration, 
viral mRNA production and nuclear export, viral protein translation, virion assembly, 
budding and maturation (reviewed in Fields Virology (11), Figure 1-2).  
The viral entry step is initiated when gp120 binds to the CD4 receptor on the cell surface 
of the target cells. CD4 binding alone, however, is not sufficient for virus entry. A 
subsequent conformational change in gp120 promotes its additional engagement with co-
receptor molecules including CCR5 and CXCR4 on macrophages and T cells, 
respectively. Viruses using CCR5 replicate well in macrophages and are termed R5- or 
M-tropic viruses while viruses using CXCR4 mainly infect T cells and are termed X4- or 
T-tropic viruses. In addition, there are some dual tropic HIV-1 isolates that can infect 
both cell types (35, 36). After gp41-mediated lipid fusion of the viral and cellular 
membranes, the uncoating process exposes the PIC in which MA, RT, IN and Vpr remain 
associated with the viral RNA genome. RT then completes the reverse transcription step 
to synthesize a cDNA copy of the viral genome which is transported into the nucleus as 
part of the PIC. In the nucleus, IN inserts the viral cDNA into the host chromosome, 
making HIV-1 infection a permanent genetic event in the infected host cells. Using the 
integrated proviral DNAs as templates, host RNA polymerases initiate the LTR-directed 
transcription to generate the viral mRNAs, which is markedly enhanced by Tat. 
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Figure 1-2: HIV-1 replication cycle. The critical replication steps include: (1) 
receptor/co-receptor binding; (2) membrane fusion; (3) virion uncoating; (4) reverse 
transcription; (5) PIC nuclear import; (6) viral DNA integration; (7-8) viral mRNA 
production and nuclear export; (9-10) viral protein translation and virion assembly; (11) 
virion budding and (12) virion maturation. (This figure is adapted from Fields Virology 
(11) ). 
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Unspliced or partially spliced viral mRNAs with the RRE sequence are recognized and 
transported by Rev through the cellular nuclear export machinery into cytoplasm where 
the translation of viral proteins occurs. The Env, Gag and Gag-Pol polyprotein precursors 
then gather at plasma membrane for the virus assembly and budding. NC recognizes the 
ψ –site on the viral genomic RNA and has it packaged into the newly assembled virions. 
During the virus release, PR cleaves the Gag and Gag-Pol precursors for the final virion 
maturation.    
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2. Nef 
2.1. Nef and viral pathogenesis 
Nef is one of the accessory proteins that are encoded only by HIV and SIV. In the HIV-1 
genome, the nef gene is positioned following the 3’-end of the env gene with most of its 
3’-half overlapping with the 3’-LTR (Fig. 1-1) and encodes a 27kDa protein. In SIV or 
HIV-2, the nef gene begins before the env gene ends, thus encoding longer sequences at 
the N-terminus of the gene products. Nef is one of the first synthesized viral proteins, it is 
highly expressed in infected cells and it is myristoylated at the N-terminus. While an 
approximate 30% proportion of Nef is membrane-asscoiated, Nef is found predominantly 
in the cytosol (37-39). Nef is also found to be incorporated into virions where it can be 
further processed by the viral protease (40-42). 
Although the name “Nef” stands for “Negative factor”, because some early studies 
described it as a gene suppressor for LTR-driven transcription (43, 44), it is now widely 
agreed that Nef plays a critical role in viral pathogenesis and disease progression in vivo, 
making Nef a very attractive drug target. A complication of Nef research, however, 
comes from multiplicity of various Nef functions discovered in distinct in vitro systems. 
Thus, one important goal of Nef research is to understand the independent contribution of 
each Nef activity to the totality of Nef function and to viral pathogenesis so that effective 
antiviral drugs targeting specific Nef activities can be developed. 
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Although AIDS is usually a rapidly progressive disease, less than five percent of HIV-1 
infected patients are reported as long-term non-progressors (LTNPs). These patients 
remain infected but do not succumb to AIDS even without antiviral treatment and they 
usually have very low viral titers and reasonably stable CD4+ T cell counts (45, 46). The 
most extensively studied LTNP group is the Sydney Blood Bank Cohort that comprises 
six blood product recipients who got infected with HIV-1 from a single donor (47). They 
remained free of AIDS after more than ten years of infection and it was later discovered 
that their virus isolates had a similar deletion in the nef gene. Analysis of the molecular 
nature of the virus isolates from several other LTNPs also revealed defects in nef genes 
(48-50). A study that compared the nef genes of virus isolates from AIDS and LTNP 
patients has correlated some common mutated Nef residues to AIDS progression (51). 
The possibility that the absence of an intact nef gene could be responsible for the LTNP 
phenotype is supported by observations in SIV-infected monkeys. Adult rhesus macaques 
infected with cloned SIVmac239 viruses whose nef gene was deleted were persistently 
infected with low viral loads but did not progress to AIDS (52, 53). The premature stop 
codon introduced in the nef gene of SIVmac239 reverted back to normal very rapidly post 
infection (52). Other primate infection studies using SIV variants harboring a 12-bp nef 
deletion (54) or other nef gene mutations (55, 56) reveal a similar selective pressure for 
an intact and functional nef to accelerate viral replication and disease progression in vivo.   
Construction of transgenic mice that express Nef alone in T cells offers a valuable model 
to understand the relationship between Nef and pathogensis in vivo.  Nef expression 
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exclusively in T cells was achieved by putting the nef transgenes under the control of the 
regulatory elements of CD2, CD3, TCR and CD4 genes (57-60). Transgenic Nef 
expression led to abnormal T cell development and activation, as well as subsequent T 
cell depletion. Furthermore, a severe AIDS-like disease was observed in a mouse model 
where transgenic Nef expression was limited to CD4+ T cells and cells of the 
monocyte/macrophage lineage (60). 
Collectively, in vivo studies in humans, non-human primates and transgenic mice all 
indicate Nef as a critical determinant for viral pathogenicity and disease progression.   
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2.2. Structure of Nef 
The structure of the 27kDa HIV-1 Nef protein can be described in two separate parts: a 
highly variable N-terminal membrane anchoring domain and a highly ordered C-terminal 
core domain that is well conserved among HIV-1 Nef alleles. It has been shown that PR 
is able to separates these two domains at a specific cleavage site W57L (note: all residue 
numbers in this thesis are according to the sequence of HIV-1 NL4.3 Nef) (61, 62), which 
may explain the release of Nef core domain in mature virions. The structure of HIV-1 
Nef domains has been defined in NMR solution (63, 64) as well as in crystal form (65, 66) 
(Fig. 1-3). Although very little structural work has been done for SIV or HIV-2 Nef,  
similar core domain structure can be predicted by the high similarity of the residues in 
their core domains.  
The first 6 amino acids (M1GxxxS/T) constitute the most important domain on the N-
terminal arm of HIV-1 Nef: the myristoylation sequence (67). The G2 residue is the 
myristoylation site where a myristate is covalently linked by a cellular N-myristyl 
transferase. The N-terminal myristyl modification is required for Nef to attach to the cell 
membrane and to perform most of its functions. The structure of the N-terminal domain 
of Nef has been described (64) (Fig. 1-2A). In the unmyristoylated form, the N-terminal 
domain of HIV-1 Nef is mostly unstructured with only one short alpha helix. 
Myristoylation, however, seems to stabilize the formation of a second alpha helix. Other 
than that, the N-terminal domain of Nef is very flexible and ready for conformational 
changes.  
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Figure 1-3: Structure of Nef domains. A. The structure of the N-terminal domain (aa 2-
57) of Nef in NMR solution (pdb code 1Q45). B. The structure of the Nefcore (aa 71-202) 
in crystallization (pdb code 1AVV). Secondary structures are labeled and shown as green 
for α helices and cyan for β sheets.   
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The core domain of Nef (Nefcore) contains highly ordered structures that are important for 
interactions with different cellular proteins (Fig. 1-2B). Specifically, the Nefcore consists 
of one type II helix (aa 70-77), four alpha helices, α1, α2 (aa 81-120) and α3, α4 (aa 187-
203), and a four-stranded beta sheet (aa 121-186). When the Nefcore was co-crystallized 
with the SH3 domain of Fyn, the polyproline type II helix of the Nefcore seemed to be at 
the interface, and based on this, the P72XXP motif of Nef has been known as the main 
SH3 binding site for Src family kinases such as Lck, Fyn and Hck (65, 66, 68, 69). 
Following this polyproline helix, the longer α1, α2 helices connected with a flexible loop 
form a cavity that is theoretically accessible to a potential binding partner. The two 
proline residues (P136 and P147) twist the beta sheet structure and result in two pairs of 
anti-parallel strands that contribute to the hydrophobic groove of the Nefcore. In addition, 
there is another long flexible loop between β3 and β4, which is also open for potential 
protein interactions. 
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2.3. Cellular functions of Nef 
Nef is probably the most multifunctional viral protein of HIV-1. Extensive studies have 
documented at least three major cellular activities of Nef in vitro: down-regulation of cell 
surface marker, enhancement of virus infectivity, and regulation of cell signaling and 
activation. These activities are mechanistically distinct and genetically separable, which 
means Nef requires specific motifs for specific functions (Fig. 1-4).  These three major 
cellular activities of Nef are individually reviewed below. 
2.3.1. Down-regulation of cell surface markers 
1). CD4 
The first characterized function of Nef is the down-modulation of CD4 molecules on the 
cell surface (70, 71). As one of the most important cell surface markers of helper T cells, 
CD4 plays an essential role specifically in T cell antigen recognition and subsequent 
activation by binding MHC type II molecules on antigen presenting cells (APCs). Thus, a 
stable population of CD4+ T cells must be maintained for a functional immune system. 
The clinical hallmark of immune system dysfunction caused by AIDS is the depletion of 
CD4+ T cells.  
For viral replication, CD4 serves as the primary receptor on target cells to initiate viral 
entry. However, it is to be removed post entry by viral mechanisms since constant CD4 
expression at a high level promotes super-infection, prevents virion release and interferes  
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Figure 1-4: Cellular activities of Nef. HIV-1 Nef protein is shown in light blue and the 
critical residues for each function are indicated.   
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with viral envelope trafficking (72-75). Three viral proteins, Env, Vpu and Nef, have the 
ability to down-regulate CD4 through different mechanisms (75-78). Unlike Env and Vpu 
that mainly target the newly synthesized CD4, Nef is expressed at the early stage of the 
virus life cycle and dramatically down-regulates CD4 directly from the cell surface. The 
N-terminal myristoylation sequence of Nef is required for this function (79).  
Nef has been shown to localize to clathrin-coated pits where CD4 molecules are enriched 
(80). It has been shown that the inhibition of clathrin-mediated endocytosis blocks CD4 
down-regulation induced by Nef (81). These studies suggest a model in which Nef down-
regulates CD4 by inducing clathrin-mediated internalization of these molecules from the 
cell surface and directing them to the endocytosis machinery for degradation. The 
internalization of CD4 by Nef involves direct binding of Nef to the cytoplasmic domain 
of CD4 (82), which has also been confirmed by the NMR analysis (83). The W57L motif 
of Nef seems to be at the interface of this interaction and is functionally required for CD4 
down-regulation (84). After CD4 is internalized, Nef binds adaptor protein 2 (AP-2) that 
targets Nef-associated CD4 to lysosomes. The major motif of Nef for binding AP-2 has 
been mapped to the dileucine L164L in the flexible loop (aa 148-180) within the Nefcore 
(63, 85, 86). A second diacidic motif D174D within the same loop seems to enhance this 
interaction (87). Mutation of either the L164L or the D174D motif to alanines abrogates 
CD4 down-regulation by Nef. In addition, another motif responsible for CD4 down-
regulation has been mapped to E154E. This motif is required for the interaction of Nef 
with -COP which directs CD4 from endosomes to lysosomes for degradation (88). 
Recently, ubiquitination of the K144 residue of Nef was found to be important for CD4 
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down-regulation, which indicated another pathway of Nef-mediated receptor degradation 
(89). Finally, CD4 down-regulation can also be regulated by the P122D motif of Nef by an 
unknown mechanism (90).  
 2). MHC-I 
Major histocompatibility complex class I (MHC-I) represents another group of important 
cell surface markers down-regulated by Nef (91). Normally, MHC-I displays the  
peptides of foreign antigens, for example those of the viral proteins in the host cells, to 
CD8+ cytotoxic T (CTL) cells so that infected cells can be killed. This immune response 
is further enhanced by natural killer cells (NK) that can neutralize cells exhibiting an 
abnormal reduction of MHC-I expression. Nevertheless, Nef seems to keep the balance 
for HIV-1 infected cells to evade both CTL attack and NK surveillance by selectively 
removing particular groups of cell surface MHC-I molecules, HLA-A, B, but not HLA-C, 
E (92). The functions of Nef to down-regulate MHC-I and CD4 are mechanistically and 
genetically separate. Currently, there are at least two models of MHC-I down-regulation: 
one is focused on the phosphofurin acidic cluster sorting protein (PACS) and the other on 
the adaptor protein (AP).  
An early study has suggested a PACS-dependent pathway of MHC-I down-regulation by 
demonstrating the interaction between Nef and PACS-1 (93). This interaction seems to 
override the ADP-ribosylation factor 6 (ARF6)-related endocytosis pathway in a 
phosoinositide 3 kinase (PI3K)–dependent manner, and as a result, MHC-I is directed to 
and retained in the trans-golgi network (TGN) (94). Recently, the PACS model has been 
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updated with studies on the Nef/PACS-2 complex and more details especially regarding 
the kinase cascade have been revealed (95, 96). It has been shown that once the 
Nef/PACS-2 complex arrives at the TGN, PACS-2 is detached while Src-family tyrosine 
kinase (SFK) binds Nef to phosphorylate a zeta chain associated protein 70kDa (ZAP70). 
ZAP70 then activates PI3K which leads to GTP loading of ARF6. This eventually 
accelerates the endocytosis of MHC-I molecules. Therefore, two Nef motifs appear to be 
critical for MHC-I down-regulation: the acidic E62EEE domain required for the PACS 
binding and the polyproline P72XXP domain important for SFK association. 
The AP-dependent model is based on a ternary complex consisting of Nef, AP-1 and 
MHC-I (97, 98). In this model, Nef serves as a connector since AP-1 does not directly 
bind the cytoplasmic tail of MHC-1.  This complex may direct newly synthesized MHC-I 
from the TGN to intracellular lysosomes for degradation. Interesting, formation of the 
complex is independent of the canonical AP binding motif L164L; instead, it requires the 
same E62EEE and P72XXP motifs as in the PACS-dependent model of MHC-I down-
regualation. Indeed, some data support that the E62EEE actually mediates the association 
of Nef with AP rather than with PACS (99). At present, whether and how these two 
models can be consolidated remains unknown.   
3). CD3  
Nef-dependent CD3 down-regulation is not conserved among Nef alleles. While most 
SIVs from old world monkeys such as SIVsm and their close relative HIV-2 encode Nefs 
with the ability to down-regulate CD3, this function appears to be lost in SIVcpz, and this 
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functional loss may have occured in HIV-1 (100). This raises an interesting explanation 
for the non-pathogenicity of most SIVs and HIV-2 in their natural hosts which is in 
contrast to the severe virulence of HIV-1 in humans. The hypothesis correlates the 
pathogenicity of lentiviruses with the ability of their Nef proteins to down-regulate CD3. 
By down-regulating CD3, SIVs and HIV-2 Nef proteins may help to prevent the 
hyperactivation of infected T cells and subsequent cell death. Since HIV-1 Nef fails to 
down-regulate CD3, HIV-1 infection in humans may proceed to AIDS more readily due 
to dramatic T cell loss and collapse of the immune system. 
However, this model has been challenged due to the difficulty to explain some exceptions. 
The non-pathogenicity of SIV and HIV-2 is not absolute. When the species barrier is 
crossed, SIVsm can cause AIDS in rhesus macaques and black mangabeys, although their 
Nef proteins are still capable of down-regulating CD3 (101, 102). Even in natural hosts, 
there are exceptional cases of AIDS for SIVsm and HIV-2 infection with down-
regulation of CD3 by functional Nefs (103-105). In the case of patients with dual 
infection of HIV-1 and HIV-2, CD3 down-regulation by HIV-2 Nef does not prevent 
AIDS progression caused by HIV-1 (106).  
The significance and mechanism of CD3 down-regulation remains unclear in HIV-1 
infection. Therefore, a priority is to identify the Nef domain that is responsible for CD3 
down-regulation before the hypothesized rule can be further evaluated. Thorough 
determination of whether HIV-1 with a Nef mutant able to down-regulate CD3 loses its 
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pathogenicity, or alternatively, whether SIVs become virulent with a Nef mutant that fails 
to down-regulate CD3, needs to be performed.  
4). Chemokine receptors 
Chemokine receptors are important cell surface proteins normally found on leukocytes. 
They bind chemokines that induce leukocyte activation and migration. Active secretion 
of chemokines acts like a triggered alarm to the immune system, recruiting leukocytes 
into tissues where they are needed for a proper immune response. In the case of HIV-1 
infection, two chemokine receptors CXCR4 and CCR5 serve as the co-receptors for viral 
entry and thus determine the tropism of HIV-1 infection. In the early stage of HIV-1 
infection, viruses seem to prefer CCR5, whereas in the late stage of AIDS progression 
viruses tend to switch to use CXCR4 (107). Genetically, a 32bp deletion mutant of CCR5 
(CCR532) has been reported to confer resistance to HIV-1 infection in an infected slow 
progressor (108), suggesting CCR5 as an attractive antiviral target.  
As with CD4 down-regulation, Nef induces CXCR4 and CCR5 down-regulation to 
prevent superinfection (72, 109, 110). This activity is conserved among HIV-1, HIV-2 
and SIV Nef proteins. CCR5 down-regulation is mediated by Nef probably through a 
similar endocytosis mechanism, since the signature motifs are mapped to P72XXP and 
E62EEE that are responsible for MHC-I down-regulation (111). 
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2.3.2 Enhancement of virus infectivity 
Although Nef is not strictly required for viral replication in cell cultures, evidence from 
several groups has suggested that Nef functions to enhance infectivity of progeny virions 
(41, 112-115). This Nef function, however, appears to vary depending on the viral 
isolates. For example, HIV-1 SF2 Nef could increase viral infectivity by 38-fold while 
NL4.3 Nef only induced a 3-fold increase tested in the same assay (116). The Nef protein 
encoded by HIV-1 F12 strain even reduced virus infectivity, and interestingly, the 
inhibitory effect could be transferred to HIV-1 NL4.3 Nef with a single amino acid 
change E177/G (117), suggesting Nef harbors determinants for virus infectivity. Like most 
HIV-1 Nef alleles, SIV Nef is also able to enhance virus infectivity and they are 
functionally interchangeable (118).   
Expression of Nef in virus-producing cells rather than in target cells is believed to 
enhance infectivity of progeny virions (113-115). To be functional, Nef must be attached 
to the cell membrane and N-terminal myristoylation of Nef is required (41). Nef may 
enhance virus infectivity via specific attachment to lipid rafts (119, 120). However, this 
seems to be at odds with the result that MA, which controls the viral interaction with lipid, 
is not a target of Nef to boost infectivity (121), as well as the observation that a Nef 
mutant that is highly accumulated in lipid rafts fails to enhance infectivity (122). 
Contradictory results have been shown regarding whether Nef has to be packaged into 
virions to enhance infectivity. On one hand, blocking the binding of a fusion protein 
CypA-Nef to Gag prevents its incorporation into virions and inhibits its infectivity 
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enhancement effect (123). Yet in another experiment, virion-associated Nef did not 
enhance virus infectivity when it was packaged as a Nef-CS-Vpr fusion and was released 
into virions after processed by viral protease (124). Furthermore, most packaged Nef 
proteins are processed by PR into the Nefcore domain, but they are not sufficient to 
increase virus infectivity and the cleavage by PR is believed to be functionally irrelevant 
(125, 126).   
Nef enhances the infectivity of HIV-1 viruses with both X4- and R5-tropic envelopes as 
well as viruses pseudotyped with amphotropic MLV envelope (127). However, similar 
effects were not observed with VSV-G- and Ebola-GP-pseudotyped viruses (128), which 
undergo a low-pH dependent endocytosis pathway for viral entry. A possible explanation 
is that Nef alters an actin cytoskeleton barrier in target cells that blocks post entry 
infection of ΔNef virus (129), and low pH-dependent envelopes may bypass the actin 
structure barrier by transporting ΔNef virus through the endocytosis machinery. 
Moreover, HIV-1 Nef is proposed to enhance virus infectivity, at least partly, by 
increasing the virion incorporation of viral envelope products (130). 
The infectivity enhancement function of Nef can be uncoupled from other Nef functions 
in vitro. Although defective Nef mutants in terms of CD4 and MHC-I down-regulation as 
well as Pak2 association may still be able to enhance virus infectivity (126, 131, 132), 
mutations in the L174L motif responsible for AP-mediated CD4 down-regulation impaired 
the infectivity enhancement of Nef (133). In support of this, the infectivity enhancement 
by Nef was highly dependent on its cellular binding partner Dynamin 2 (Dyn2), which is 
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also needed for clathrin-dependent endocytosis induced by Nef. Presumably, Nef may 
bind Dyn2 to optimize virus infectiviy by down-regulating a potential restriction factor 
that targets Env in producer cells through the endocytosis pathway (134). 
2.3.3. Regulation of cell signaling and activation 
Efficient HIV-1 replication and spread is highly restricted in quiescent T cells as well as 
in undifferentiated monocytes. Proper activation and differentiation of these natural target 
cells of HIV-1 seems to enhance viral propagation. Nef is a possible factor to regulate 
cell activation by hijacking signaling pathways through its interaction with cellular 
kinases, among which Pak2 and Hck are the most extensively studied. 
1). Pak2 
Pak2 is a well-known Nef-associating kinase (NAK). Initial studies identified a cellular 
serine kinase that co-immunoprecipitated with Nef in human T lymphocytes (135). This 
serine kinase was later defined as a p21-associated kinase 2 (Pak2) that was activated by 
Rac and Cdc42 (136-138). Nef not only binds Pak2 but also has the ability to activate 
Pak2 (139), and this seems to be a common feature of HIV and SIV Nef proteins (139, 
140). 
Mutational analysis has determined several critical Nef domains for Pak2 association and 
activation. A specific determinant of Nef/Pak2 interaction has been mapped to L85, H89, 
R188 and F191, which are proposed to form the hydrophobic binding surface for Pak2 
(141). Substitution of these residues specifically prevents Pak2 association without 
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affecting other Nef functions such as CD4 or MHC-I down-regulation (141). Several 
other motifs are also indispensable. Mutating the myristoylation site residue G2 severely 
impairs formation of the Nef/Pak2 complex suggesting the importance of membrane 
anchoring of Nef for Pak2 association (142, 143). The SH3 binding motif P72XXP is 
required for Pak2 activation possibly by the recruitment of Vav rather than by structurally 
participating in direct binding interaction (143-145). Moreover, mutation of two arginine 
residues R105R abrogates Pak2 association and activation (143), but the mechanism is yet 
to be determined. It should be noted that mutation of G2, P72XXP or R105R also has some 
impacts on other Nef activities such as CD4 and MHC-I down-regulation.  
The pathological significance of Nef/Pak2 interaction is still controversial. Nef-induced 
Pak2 activation may lead to T cell activation which stimulates viral replication (136, 146), 
or alternatively may trigger anti-apoptotic signaling pathways in infected T cells which 
might contribute to maintaining a virus reservoir (147, 148). However, a Pak2-binding 
deficient mutant F191R has hardly any effect on HIV-1 replication, T cell activation or 
apoptosis (149). Neverthless, Nef-induced Pak2 activation seems to be dependent on 
another Nef binding partner: a guanine nucleotide exchange factor Vav, and the 
interaction between Nef and Vav may lead to cytoskeletal rearrangements (145). If the 
actin barrier does exist for HIV-1 infection, the correlation of Pak2 activation with 
infectivity enhancement by Nef might be partly explained (143).  
2). Hck 
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Nef has been reported to interact with several Src family tyrosine kinases (SFK). The 
interaction between Nef and the tyrosine kinase Hck is the best characterized. The 
structure of the Nef/Hck complex has been solved and the interaction involves the 
polyproline motif P72XXP of Nef and the SH3 domain of the kinase (63). Nef requires the 
same P72XXP motif to interact with other SFKs such as Lyn, Lck, Fyn and Src (65, 66, 
68, 150), but its interaction with Hck shows the highest affinity (69). While HIV-1 Nef 
proteins mainly target Hck and Lyn, SIV Nef proteins prefer Fyn and Src due to the three 
amino acid changes within the “hydrophobic pocket” proximal to the SH3 binding 
domain (151).  
Hck is specifically expressed in myeloid cells such as macrophages and neutrophils (152). 
The biological function of Hck is implicated in actin-dependent phagocytosis and 
migration (153). Nef promotes Hck catalytic activity by tightly binding to the SH3 
binding domain of Hck (154). Dimerization of Nef seems to enhance Hck activation 
(155).  It has also been shown that Nef activates endogenous Hck in myeloid TF1 cells 
regardless of Nef myristoylation status (156), thus it can be inferred that the majority of 
Hck activated by Nef may represent the cytoplasmic pool of Hck. Indeed, Hck is 
expressed in two isoforms p59 and p61 that localize differently within cells (157). Since 
the p59 isoform is more enriched in the plasma membrane than the p61 isoform, it is not 
surprising that the expression of active p59 and p61 triggers distinct functions; active p59 
leads to membrane protrusion while active p61 changes the intracellular actin structure 
(158, 159). However, the significance of Hck activation for HIV-1 pathogenesis is 
currently unknown. 
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3. Macrophage and HIV-1 infection 
The major target cells of HIV-1 infection are CD4+ T cells and macrophages. As the 
disease slowly progresses to AIDS, a dramatic depletion of CD4+ T cells causes 
opportunistic infection, tissue degeneration and ultimately host death. This highlights the 
leading role that CD4+ T cells play in HIV-1 infection. However, studies on target cells 
of macrophage lineage have demonstrated crucial roles for macrophages in HIV-1 
infection. 
The initial establishment of HIV-1 infection may rely on macrophages. During HIV-1 
transmission, macrophages are among the first infected cells. Several reports have 
documented that in the seronegative patients with acute HIV-1 infection, virus isolation 
from blood is limited in monocytes but not in T cells (160, 161). Cultured blood 
monocytes were shown to support efficient propagation of some primary HIV isolates 
with high levels of progeny virus production (162). In line with these observations, most 
viruses seem to use CCR5 in the early stage of HIV-1 infection (107), probably 
suggesting a viral preference of targeting macrophages to initiate HIV-1 infection. 
Moreover, in certain tissues such as brain, lung and gut (163-165), macrophages 
represent the predominant HIV-1 infected cells.  
Macrophages make a great contribution to the dissemination of HIV-1 virus particles. 
HIV-1 virus particles can be transmitted from macrophages to T cells in multiple ways. 
Viral dissemination can be mediated by cell-cell fusion between infected macrophages 
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and CD4+ lymphocytes or by the formation of a transit “virologic synapse” that rapidly 
transfers virus particles from infected macrophages to T lymphocytes (166). Alternatively, 
macrophages may also present virus particles to T cells in a similar way that APCs 
present antigens to activate helper T cells. In addition, macrophages specifically deliver 
virus particles to certain tissues. The HIV-1 infected circulating monocytes in blood are 
described as the “Trojan horse” that carry HIV-1 virus across the blood brain barrier 
(167). Once in the brain, they differentiate into macrophages and release virions. 
Similarly, infected circulating monocytes can travel to the gastrointestinal tract and 
differentiate into macrophages to initiate infection in intestine (168). Moreover, HIV-1 
infection can be transmitted between individuals via bodily fluids such as semen and 
vaginal secretions in which the predominant cells are macrophages.  
Macrophages maintain a major viral reservoir for continuous HIV-1 infection. Most HIV-
1 infected T cells are killed by lytic HIV-1 infection. In contrast, HIV-1 infection in 
macrophages seems to occur in a milder way. Several mechanisms may account for the 
low level of HIV-1 cytopathicity in macrophages. For example, monocytes hardly have 
any cell surface CD4 molecules, and even after full differentiation, macrophages express 
much less cell surface CD4 than T cells. This low level of receptor expression not only 
limits initial viral entry but also prevents surperinfection. Indeed, the low level of post 
entry infection in macrophages is characterized by poor reverse transcription and a slower 
virus life cycle due to a limited dNTP pool (169). Low levels of HIV-1 infection in 
macrophages are usually associated with much less virus-induced cytopathic effect. 
Therefore, infected macrophages may still exist in the late stage of HIV-1 infection when 
 
 
32 
 
most CD4+ T cells are already depleted. In addition, HIV-1 infection triggers anti-
apoptosis signaling in macrophages. The viral protein Nef, for example, is involved in 
several anti-apoptosis mechanisms: Nef-induced NF-κB activation is reported to inhibit 
TNFα-mediated apoptosis (170); Nef prevents apoptosis by inactivating pro-apoptosis 
factor Bad (171); Nef also affects the p53-mediated apoptosis pathway (172). 
Furthermore, macrophages not only survive longer in HIV-1 infection but also harbor 
virus particles. Virion assembly has been observed in the intracellular compartments of 
infected macrophages (173, 174), providing virus particles with a hidden storage place 
that is free of host immune responses. More importantly, it has been shown that even 
after macrophage infection is blocked for several weeks, the recovered intracellular virus 
particles can be transmitted to peripheral blood lymphocytes (175). Collectively, as long 
survivors in HIV-1 infection, macrophages maintain a hidden but continuous viral 
reservoir for HIV-1 infection. 
Macrophages may also regulate HIV-1 infection by manipulating lymphocyte activities. 
Generally, macrophages provide innate immunity against foreign pathogens and amplify 
the immune response by activating cellular and humoral immunity. This is usually 
achieved through a variety of chemokines and cytokines that are produced by 
macrophages to regulate normal lymphocytes activities. In the case of HIV-1 infection, 
however, infected macrophages actually manipulate these regulatory signals for viral 
benefits, resulting in enhanced viral infection and damage to both T- and B-lymphocytes. 
Indeed, several HIV-1 proteins have the ability to induce cytokine and chemokine 
production during HIV-1 infection, which will be reviewed in detail in the chapter I-4.   
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Productive infection of T cells is hard to establish in tissues where only a limited amount 
of resting T cells are available. Nevertheless, a few HIV-1 infected macrophages are able 
to recruit as well as to activate target cells and therefore facilitate efficient virus spread in 
T cells (1). Infected macrophages also determine the fate of T cells. Models of selective 
killing of both CD4+ and CD8+ T cells by infected macrophages have been demonstrated. 
During HIV-1 infection, the expression of FasL and TNF is upregulated on 
macrophages while their receptors are highly expressed on CD4+ and CD8+ T cells. 
Thus, death of T cells is regulated by infected macrophages through FasL- and TNF-
mediated apoptosis pathways, an indirect mechanism of T cell depletion that contributes 
to HIV-1 pathogenesis (176). In addition, infected macrophages are able to regulate HIV-
1 latency in T cells. It has been shown that latent viruses in macrophages can be 
reactivated after CD40L stimulation, and interestingly autocrine secreted TNF from 
activated macrophages also reactivates latent HIV-1 in bystander T cells (177), 
suggesting a possible mechanism of the reactivation of HIV-1 latency in T cells by 
macrophages.  Moreover, infected macrophages mediate dysregulation of B cells. Recent 
findings have explained how the viral Nef protein expressed by macrophages causes 
dysregulated B cell activation. The hyperactivity of B cells has been linked to ferritin 
production induced by Nef in infected macrophages (178). However, another model 
shows that Nef can be transferred from macrophages to B cells through cell-cell contact 
and the presence of Nef in B cells leads to disruption of class-switch recombination and 
subsequent B cell dysfunction (179).  
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4. Cytokine and chemokine production during HIV-1 infection 
Most viral infections trigger acute and strong immune responses in infected cells. These 
events constitute the first line of antiviral defense to reduce viral replication and to limit 
viral spread. One important antiviral event is the production of specific cytokines and 
chemokines by infected cells. The functions of these molecules are not limited to innate 
immunity but also stimulate the second wave defense of humoral and cellular immunity. 
Indeed, cytokines and chemokines regulate the distribution, activation, development and 
mortality of all kinds of immune cells.  
Studies of HIV-1 infection have documented a long list of cytokines and chemokines, 
which includes but is not limited to IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, IL-15, IL-
16, TNF-, TGF-, IFN-, IFN-, IFN-, MIP-1, MIP-1, MCP-1 and RANTES (1, 
180-199). (Note: MCP-1, MIP-1, MIP-1 and RANTES are now known as CCL2, 
CCL3, CCL4 and CCL5, respectively. However, their original names are used in this 
thesis.) The effect of cytokines and chemokines on HIV-1 infection may be positive (IL-1, 
IL-6, TNF-), negative (IL-10, IL-13, IL-15, IFN-, IFN-, RANTES), or dual (IL-4, 
IFN-, MIP-1, MIP-1) (1, 200, 201). Interestingly, a cytokine profile switch from Th1- 
to Th2- type, characterized by the loss of IL-2 and IFN- as well as the increase of IL-4 
and IL-10 in the late stage of HIV-1 infection, seems to be correlated with AIDS 
development (202). In addition, a few cytokines have been reported as neurotoxic factors 
(203, 204). In summary, HIV-1 infection and disease progression is under profound 
regulation by complex signaling networks triggered by a variety of cytokines and 
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chemokines. The net effect, however, seems to result in more viral benefits than host 
defense. Indeed, several HIV-1 viral proteins such as Env, Tat, Vpr and Nef purposefully 
participate in the induction of specific cytokines or chemokines as well as in the 
manipulation of cellular signaling pathways, and thus convert the host antiviral 
machinery to viral advantage.    
The gp120 unit of Env interacts with the receptor CD4 and the co-receptor CXCR4 and 
CCR5, which is already sufficient to trigger signaling pathways. It has been demonstrated 
that gp120 is able to activate all three mitogen-activated protein kinase (MAPK) family 
kinases ERK1/2, JNK and p38 in macrophages (205-207). Therefore, MAPK pathway 
activation might play a central role in gp120-induce signaling transduction. The upstream 
signaling events triggered by gp120-CD4 interaction and by gp120-CXCR4/CCR5 
interaction may be different: gp120-CD4 interaction leads to the activation of two kinases 
Lck and Raf-1 through a Ras-dependent signaling pathway (208), whereas gp120 
engagement with CCR5 activates kinases such as Lyn, PI3K and Pyk2 (209-211). The 
central downstream event of MAPK activation seems to be the release of TNF- (212), 
one of the most potent NF-B activators. Subsequent NF-B activation may induce the 
production of other cytokines and chemokines. The full list of gp120-induced cytokines 
and chemokines includes IL-1, IL-4, IL-6, IL-8, IL-10, IL-13, TNF-, IFN-, IFN-, 
IFN- [182-187]. At present, an in-depth understanding of how gp120-activated signaling 
pathways are linked to the synthesis of each cytokine/chemokine is still missing. 
Tat is another active inducer of a few cytokines and chemokines such as IL-1, IL-2, IL-6, 
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IL-8, TNF- and MCP-1 [188-194]. The increased expression of IL-2 by Tat is regulated 
primarily at the transcriptional level. The expression of Tat activates the IL-2 promoter, 
and both the NF-B and NF-AT sites of the promoter are required (192, 213). Similarly, 
Tat mediates the synergistic increase of MCP-1 promoter activation by enhancing the 
binding activities of SP1, AP1 and NF-B (189). In addition, Tat is also able to enhance 
the DNA binding activity of NF-B, which increases IL-6 expression (214). These results 
suggest a central role of NF-B in Tat-mediated induction of cytokines and chemokines. 
In fact, Tat is able to activate NF-B via the IKK pathway, and PKC activation by Tat 
has been shown to facilitate the nuclear translocation of NF-B (215, 216).  
Vpr seems to have a dual effect on cytokine/chemokine regulation. An early finding 
showed that Vpr suppressed expression of IL-2, IL-4, IL-10, IL-12, TNF- by inhibiting 
NF-B activation via I-B in T cells (217). The Vpr-induced suppression of IL-12 but 
not IL-10 was observed in macrophages (218). In addition, extracellular as well as virion-
associated Vpr was reported to down-regulate -chemokines, including MIP-1, MIP-1 
and RANTES, in PBLs and macrophages (219). In contrast to these suppressive effects, 
other results demonstrated that the activation of NF-B and C/EBP by Vpr increased the 
expression of IL-8 in primary T cells and macrophages, as well as the expression of IL-6, 
IL-10, TNF- and IFN- in a variety of cell types (193). In addition to the cytokine 
production regulated by Vpr, the production of -chemokine RANTES in microglial cells 
was also induced by HIV-1 infection in a Vpr- and Nef- dependent manner (220). The 
regulatory function of Vpr on cytokine and chemokine production seems to be 
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determined by the dual effect of Vpr on NF-B activation. Therefore, it is of great 
interest to study how Vpr manages to manipulate the bidirectional switch of the NF-B 
signaling pathways. 
Among all the HIV-1 viral proteins, Nef is probably the most competent regulator of 
cytokine and chemokine production. Nef is predominantly cytoplasmic and about 30% of 
Nef protein is membrane-associated. Although the concept of extracellular Nef is still 
controversial, Nef has been shown to be packaged into virions during assembly and may 
be secreted in exosomes (221). Nevertheless, despite the existing forms of Nef, 
suppression and induction of cytokines/chemokines by Nef have been widely reported in 
various cell types through distinct mechanisms. A simple regulation by Nef may not 
necessarily involve direct activation of signaling pathways. For example, Nef down-
regulates MHC-I on APC and reduces CTL activation, which indirectly results in 
cytokine suppression in CTLs. Another example is that Nef can regulate membrane-
associated cytokines such as TNF molecules via its ability to affect their internalization 
rate (222).  
However, it is believed that complicated signaling pathways activated by Nef are 
involved during cytokine/chemokine regulation and sometimes may cause contradictory 
effects. For example, it was found that the expression of Nef interfered with IL-2 
induction at the transcriptional level in T cells (223), and this suppressive effect was also 
observed by another group who confirmed that Nef expression in T cells down-regulated 
IL-2 as well as IFN- without affecting IL-4, IL-9, IL-13, IL-8 and TNF- expression 
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(224). However, opposite findings suggested that Nef expression in T cells enhanced IL-2 
production via a PI3K-dependent pathway (225, 226). The discrepancy of the cytokine 
profiles might be simply due to the differences of cell cultures, Nef isolates and T cell 
stimulation methods, or more profoundly it might reflect a complex signaling network 
that Nef manipulates in T cells. In monocytic cells, Nef may have a more consistent 
upregulating effect on the secretion of cytokines and chemokines. A few studies using 
recombinant Nef (rNef) have shown that extracellular Nef is sufficient to induce 
cytokines and chemokines (197). In a rat model, rNef, rather than Tat or gp120, induced 
production of IL-6, TNF- and IFN- and was able to provoke leukocyte recruitment into 
the central nervous system (CNS) (227).  The induction of IL-10 by rNef has been shown 
to rely on a calmodulin-dependent pathway (196). In addition, rNef selectively 
upregulated IL-15 synthesis in the macrophage population, which induced the activation 
and proliferation of unstimulated PMBCs, as well as the increased production of IFN-, 
TNF- and IL-6 (194). However, it is not fully understood how extracellular Nef triggers 
signaling pathways and to what extent this represents the natural biological events 
mediated by Nef during HIV-1 infection. Presumably, extracellular Nef may bind to a 
cell surface receptor or may somehow enter the cells to initiate signaling. At present, the 
latter seems possible since it has been reported that rNef is efficiently internalized by 
macrophages and induces release of cytokines and chemokines such as IL-1, IL-6, TNF-
, MIP-1 and MIP-, and the Nef-dependent cytokine/chemokine release is associated 
with NF-B activation (197). IB and all three MAPKs (ERK1/2, JNK and p38) are 
activated in this rNef-activated pathway (228). In agreement with this, rNef also induces 
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activation of NF-B and AP-1 in U937 monocytic cell line through IB degradation and 
JNK activation (229).  
In comparison to results involving treatment with rNef, endogenous expression of Nef is 
a less artificial way to mimic the natural activities of Nef especially in the context of viral 
infection. The endogenous expression of Nef actively induces increased secretion of 
cytokines and chemokines in monocytic cells. However, the profiles of induced cytokines 
may vary depending on cell types. For example, expression of Nef in astrocytes mainly 
induced cytokines such as IL-2, IL-8, TNF- as well as a chemokine MCP-1 (230), 
whereas the expression of Nef in DCs induced IL-6, IL-12, TNF- as well as two 
chemokines MIP-1 and MIP-1 (198). Previous studies from our lab and others have 
focused on the manipulation of cellular signaling pathways by endogenous Nef in 
macrophages. The expression of Nef in HIV-1 infected macrophages induces a variety of 
secretory factors. Among them, two chemokines MIP-1 and MIP-1 appear to have a 
chemotactic effect on T cells (1) and probably on monocytes and macrophages as well. 
With more target cells attracted to sites of infection, HIV-1 may have a better chance to 
spread. HIV-1 replication in resting T cells is highly restricted, but endogenous Nef in 
macrophages has been shown to induce sCD23, sICAM and other unknown factors that 
eventually mediate the activation of resting T cells and make them permissive for viral 
replication (231). Moreover, the viral pathogenesis in B cells characterized by 
hyperactivation has been linked to ferritin expression in Nef-expressing macrophage 
supernatants (178). In conclusion, the dysregulated production of these regulatory 
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molecules indicates the ability of Nef to hijack the cellular signaling pathways of infected 
macrophages for viral benefits. However, the exact molecular mechanism involved in this 
Nef activity is unclear.  
5. Study aims 
The studies conducted in this thesis mainly attempt to identify the functional motif in Nef 
that is responsible for chemokine induction in macrophages as well as to clarify the 
relevance of this motif to other Nef functions. In addition, the role of Env in Nef-induced 
MIP-1β chemokine production in macrophages was determined. Distinct signaling 
pathways that regulate chemokine release by macrophages will be discussed. Finally, 
some preliminary results will be presented from the co-immunoprecipitation experiments 
performed to identify possible cellular factors that may be involved in chemokine 
regulation by Nef.   
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CHAPTER II.  
MATERIALS AND METHODS  
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1. Cell cultures (III, IV, V)  
Populations of monocytes were isolated by countercurrent centrifugal elutriation of 
mononuclear leukocyte-rich fractions of blood cells from normal donors undergoing 
leukopheresis (162). In 24-well plates, monocytes were as adherent cell monolayers  
cultured in DMEM (Gibco) medium containing monocyte colony stimulating factor 
(MCSF) (R&D system) for 2 days. Stimulated monocytes were then cultured in MCSF-
free medium for another 5 days prior to use in experiments. Elutriated PBLs were 
activated with PHA (4 mg/ml) and were cultured in RPMI containing 10% human serum 
and 64 U/ml of interleukin-2 (ICN). 
293T cells and TZM-bl cells were maintained in DMEM containing 10% Fetal Bovine 
Serum (FBS). Jurkat Tag Cell line was adopted from the lab of Dr.Heinrich Gottlinger 
and cells were maintained in RPMI containing 10% Fetal Bovine Serum (FBS).  
2. Plasmid constructs (III, IV, V) 
2.1 Proviral clones  
HIV-1 NL4.3 clone was obtained from the AIDS Reagent Program of NIAID, NIH. In 
this thesis study, ADA clone was a modified NL4.3 variant harboring the NdeI (6399) - 
BamHI (8465) envelope fragment from the M-tropic primary isolate (Fig. 2-1). ADA-
Nef was generated by replacing the first 237bp of the Nef gene in ADA with a unique  
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Figure 2-1: Construction of ADA, ADA-ΔNef and ADA-Nef.GFP fusions. The ADA 
clone was a modified NL4.3 variant harboring the NdeI (6399) - BamHI (8465) envelope 
fragment from the M-tropic primary isolate. ADA-Nef was generated by replacing the 
first 237bp of the Nef gene in ADA with a unique SrfI site, which was then used to 
subclone Nef-GFP fusion constructs. 
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SrfI site, which was then used to subclone GFP, wild-type Nef, Nef mutants or Nef-GFP 
fusion constructs (Fig. 2-1).  
The reporter virus clone pNL4-3.Luc.R-E- was obtained from the AIDS Reagent 
Program of NIAID, NIH. This clone is Nef-, Env- and Vpr- because it has a luciferase 
gene inserted in the position of Nef as well as frameshifts at 5’ of Env and the 26th amino 
acid of Vpr. 
HIV-1 NL4.3 N- is a Nef deficient clone with a frameshift mutation at the XhoI site of 
the Nef gene.  HIV-1 NL4.3 E- is an Env deficient clone with a frameshift mutation at the 
5’ of the Env gene. HIV-1 NL4.3 N-E- has both frameshift mutations in the Nef and Env 
genes. 
2.2 Expression vectors 
The SR expression vector and the SR-Nef plasmids were precious gifts from 
Dr.Heinrich Gottlinger, Umass Medical School. Point mutations K92EK/3A, W57L/AA, 
E62EEE/4A were introduced into the SR-Nef plasmid with the Quikchange II Site-
Directed Mutagenesis Kit (Stratagene).  
3. PCR-based mutagenesis (III, IV, V) 
In this thesis, Nef gene mutants were generated by PCR-based mutagenesis methods. The 
5’- and 3’- truncated Nef genes were directly amplified by PCR from pNL-4.3 using 
specific primers. A set of primers were designed so that the gene products had successive 
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15 amino acid deletions up to 90 amino acids from either N or C-terminus of Nef. For the 
convenience of western blotting analysis, all 3’- primers have extra coding sequences for 
an HA tag on the C-terminus.  
Nef-GFP fusion constructs were made by fusing GFP to the C-terminus of Nef or Nef 
mutants and an HA tag was inserted as a linker for the convenience of western blotting 
analysis. The gene fusion constructs were amplified by overlapping PCR reactions and 
then subcloned into the SrfI site of the ADA-Nef. 
Nef point mutations K92EK/3A, R105R/AA, K92/A, E93/A, K94/A, D174D/AA, E155E/AA 
were introduced into a pcDNA-Nef plasmid with the Quikchange II Site-Directed 
Mutagenesis Kit (Stratagene). Mutated genes were confirmed by sequencing, amplified 
by PCR and inserted into the SrfI cloning site of the ADA-Nef.  
4. Virus preparation and macrophage infection (III, IV, V) 
To make virus stocks, 293T cells were transfected with proviral clones using the TransIT 
transfection kit (Mirus). Pseudotyped viruses were produced by co-transfecting vectors 
expressing VSV-G, YU2 Env and NL4.3 Env. Fresh medium was changed 6 hours post 
transfection. 48 hours later, virus-containing supernatants were harvested and filtered 
with 0.22µ conical tubes (Millipore). Virus titers were normalized by reverse 
transcriptase (RT) activity.  
 
 
46 
 
Monocyte-derived-macrophage (MDM) cells were seeded in 24-well plates (7×105/well) 
and were incubated with virus stocks (2-5×106 cpm/well) overnight. The incubation time 
for VSV-G-pseudotyped virus inoculation was 2-4 hours. Viruses were then removed and 
replaced with fresh medium after cells were extensively washed. Infected cells were 
incubated at 37C and at indicated time points 500L supernatants from infected cultures 
were collected and 500L fresh medium was added back.  
5. RT assay (III, IV, V) 
To determine the titers of virus stocks, virus-containing supernatants were harvested at 48 
hours post transfection, clarified by low-speed centrifugation, and filtered through 
0.45m-pore filters prior to RT assay. A 5L sample was used for the RT assay. To 
monitor replication in infected macrophage, supernatants were collected at indicated time 
points and a10L sample was used. RT activity was measured by quantification of 3H-
TTP labeled reverse transcribed products. Briefly, virions were disrupted by adding an 
equal volume of a solution A containing 0.1% NP-40, 10mM DTT, 300 mM KCl, 100 
mM Tris-HCl (pH 7.9). Lysed virions were used for an overnight reverse transcription 
reaction in solution B with 10µCi/mL 3H-TTP. Quantification of reverse transcribed 
products was carried out with the Microbeta 1450 scintillation counter (Perkinelmer). 
6. ELISA (III, IV, V) 
Quantikine ELISA kits (R&D system) for human MIP-1β, MIP-1α, IL-6, IL-16, MCSF, 
TNF-α and IP-10 were used according to the manufacturer’s protocols to measure their 
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concentrations in 100µL macrophage supernatants. ELISA system for human ferritin was 
developed with ELISA plates coated with ferritin antibodies (DAKO) and HRP-
conjugated secondary antibody (Fitzgerald Industries International, Inc.).  
7. Western blotting analysis (III)  
To facilitate western blotting analysis, an HA tag was fused to C-terminus of Nef mutants 
alone or in the context of Nef.GFP fusion products. Transfected cells were lysed in RIPA 
buffer with cocktail tablet of protease inhibitors (Roche). Cell lysates were analyzed by 
SDS-PAGE and western blotting with a mouse monoclonal anti-HA antibody HA.11 
(Covance).  
8. Assay of CD4 and MHC-1 down-regulation (IV)  
Jurkat Tag cells were nucleofected with the SR vector expressing wild-type Nef or Nef 
mutants as well as a GFP expressing vector at a molar ratio of 3:1 (Amaxa nucleofector, 
Lonza). Twenty-four hours post-transfection, cells were washed and stained in dark with 
PE-conjugated mouse anti-human CD4 or anti-human HLA-ABC antibodies (BD 
Pharmingen) for 30 minutes. Stained cells were washed three times and analyzed by 
FACS.   
9. Neurotoxicity assay (IV) 
We used the NT2.N cell line to generate a pure and reproducible neuron cell population 
(232). NT2.N neurons were plated on poly-D-lysine and Matrigel coated 96-well plates 
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(25,000 cells per well). After 7 days, neurons were exposed to conditioned medium from 
HIV-infected macrophages. 48 hours after addition of conditioned medium, neuronal 
apoptosis was measured by Caspase-Glo 3/7 Assay (Promega) according to the 
manufacturer’s protocol. 
10. Virus infectivity assay (IV) 
We produced reporter viruses by co-transfecting 293T cells with the NL4-3.Luc.R-E- 
plasmid, a T-tropic or M-tropic envelope expression vector as well as the SR plasmid 
expressing Nef or K92EK/3A mutant. Infectivities of M-tropic viruses were examined in 
TZM-bl cells and macrophages, while infectivities of T-tropic viruses were examined in 
Ghost cells and PBLs. Virus infectivities were determined by measuring luciferase 
activities in infected cells using Bright-Glo Luciferase Assay System (Promega).  
11. Co-immunoprecipitation (IV, V) 
293T cells were transfected with vectors expressing HA- and FLAG-tagged proteins 
using the TransIT transfection kit (Mirus). After 48 hours, transfected cells were lysed in 
the lysis buffer containing 0.5% n-octyl glucoside, 20mM tris HCl pH 7.5, 100mM 
(NH4)2SO4 and 20% glycerol. The lysates were centrifuged at 15,000rpm to spin down 
cell debris for clarification. The supernatants were immunoprecipitated with anti-HA 
antibody HA.11 (Covance). Immunoprecipitates were analyzed by SDS page and 
immunoblotting with antisera against the PRD of Dyn2 (Affinity BioReagents) or anti-
FLAG antibody M2 (Sigma), or silver staining. 
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12. Reagents (V) 
The CD40L was supplied by Alexis Corporation.  
The anti- human CD4 antibody (clone RPA-T4) that was able to inhibit HIV-1 by 
blocking gp120 was purchased from BD Pharmingen. 
The CCR5 antagonist TAK779 was a gift from Dr. Paul Clapham, Umass Medical school. 
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CHAPTER III.  
A NOVEL MOTIF IN HIV-1 NEF THAT 
REGULATES MIP-1β CHEMOKINE RELEASE IN 
MACROPHAGES.  
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Abstract 
All primate lentiviruses encode Nef, an accessory protein that is critical for viral 
pathogenicity in vivo. Multiple cellular functions of Nef have been described in vitro and 
important functional motifs for these functions have been identified. We have previously 
demonstrated that HIV-1 Nef regulates the release of chemokine MIP-1β from infected 
macrophages and have proposed that this may enhance conditions for viral replication by 
promoting recruitment of substrate lymphocytes to sites of infection. However, the Nef 
motif responsible for this function is unknown. In the current study, we first examined 
several previously identified Nef motifs but excluded their roles in chemokine induction 
by Nef. By mutagenesis analysis, we mapped the functional domain to a region between 
residue 84 and residue 116 of HIV-1 NL4.3 Nef. In this region, we identified a novel 
motif (K92EK) that was required for Nef-dependent chemokine production by HIV-1 
infected macrophages. Importantly, the KEK motif is functionally conserved in 
SIVmac239 Nef. This further underscores Nef-induced chemokine regulation as an 
important cellular activity in viral replication and pathogenicity. 
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Introduction 
The Nef protein of primate lentiviruses is important for viral replication and 
pathogenicity in vivo. Patients infected with Nef-defective viruses have undetectable viral 
loads and do not exhibit clinical manifestations of AIDS (47, 233). Extensive studies 
have described distinct cellular functions that may explain the critical role of Nef in HIV-
1 infection in vivo. The first characterized property of Nef is its ability to induce down-
modulation of cell surface molecules such as CD4 and MHC-I, which results in enhanced 
viral replication as well as impaired host immune responses. Nef also enhances virus 
production and infectivity. It has been shown that Nef, in viruses lacking Vpu, appears to 
counteract a cellular restriction factor tetherin/BST2 and enhance virus budding (234, 
235). Several groups have suggested that more infectious progeny virions are produced in 
the presence of Nef. Finally, Nef harbors multiple motifs that can potentially manipulate 
cellular signaling pathways through engagement of cellular proteins such as Hck, Pak2 
and Vav (138, 236, 237).  For most Nef functions described above, distinct functional 
motifs in Nef have been identified, which greatly contributes to in-depth understanding of 
the molecular mechanisms for the corresponding Nef functions.  
A potential role of Nef in altering macrophages functions was first indicated in an early 
study with an SIV/macaque model in which a Nef variant confered on SIVmac239 the 
ability to replicate in resting PBMCs consisting of resting lymphocytes and 
monocyte/macrophages (238). Interestingly, although viral replication was found 
predominantly in resting T cells, it was highly dependent on the presence of macrophages. 
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How resting T cells in culture with macrophages became supportive of productive viral 
replication was not fully understood. The question has been addressed by our previous 
studies suggesting that macrophage is an important site of Nef action. Upon HIV-1 
infection, macrophages release a variety of regulatory molecules; these include two CC-
chemokines MIP-1 and MIP-1 that promote recruitment of T cells (1), sCD23, sICAM 
and probably other unknown factors that mediate activation of resting T cells (231), as 
well as ferritin that causes hyperactivation of B cells (178). Importantly, the viral protein 
Nef is necessary and sufficient to induce production of these molecules by infected 
macrophages. Since Nef has the ability to interact with cellular kinases, we have 
proposed a model in which Nef mediates secretion of regulatory molecules to enhance 
conditions for viral replication and dissemination by manipulating cellular signaling 
pathways in macrophages. This raises an essential question as what is the exact molecular 
mechanism of this Nef activity, and undoubtedly identification of the required motif in 
Nef is the first step to an answer.  
Nef actually induces a wide range of regulatory molecules in macrophages. Some of them 
such as TNF-α were detected in one study but not in another (1, 197). However, potent 
induction of chemokine MIP-1 by Nef has been consistently reported indicating that it 
represents a reproducible activity of Nef that is least affected by different experimental 
conditions (1, 197, 199). Therefore, in this thesis, we mainly focused on MIP-1 
induction in the context of viral replication as the major index of Nef-induced 
cytokine/chemokine production.  
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In this chapter, we first tested whether several previously identified Nef motifs were 
required for chemokine induction and the results showed that they were dispensable. The 
mutagensis analyses mapped the functional domain to a region between residue 84 and 
residue 116 of HIV-1 NL4.3 Nef. We next tested several point mutants in this region and 
identified a novel motif (K92EK) that was required for chemokine induction. Moreover, 
the KEK motif was also functionally conserved in SIVmac239 Nef since corresponding 
mutations also impaired MIP-1 induction by SIVmac239 Nef. This further indicates 
Nef-induced chemokine regulation may be an important cellular activity in viral 
replication and pathogenicity. 
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Results 
Nef induces MIP-1β production independently of other classical Nef 
activities. 
Before the activity of Nef-regulated cytokine/chemokine production was recognized, the 
classical functions of HIV-1 Nef were characterized into three major categories: 1) down-
regulation of cell surface molecules such as CD4 and MHC-I; 2) enhancement of virus 
infectivity; 3) interaction with cellular kinases such as Pak2 and Hck. Distinct motifs 
required for these functions have been identified (reviewed in chapter I). Some seem to 
be solely responsible for a single function. For example, L164L and E62EEE are required 
for down-regulation of CD4 and MHC-I, respectively, but are largely dispensable for 
enhancement of infectivity or engagement with Hck. However, mutations in 
myristoylation site G2, dimerization site P122D and SH3 binding interface P72XXP impair 
many Nef activities.  
The relevance of these classical Nef activities to chemokine induction is unknown. To 
address this, we examined MIP-1β chemokine induction by several representative Nef 
mutants, G2/A, P122D/AA, L164L/AA, E62EEE/4A and P72XXP/2A, which were defective 
in at least one or more classical Nef functions. Macrophages were infected with 
macrophage-tropic recombinant viruses that harbor Nef mutations as indicated along with 
wild-type and ΔNef viruses (Fig. 3-1). Although all viruses exhibited robust growth in 
macrophage culture, the wild-type Nef virus induced at least 10-fold higher MIP-1  
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Figure 3-1: Nef induces MIP-1β production independently of its other classical 
functions. Macrophages were infected by HIV-1 recombinant viruses harboring wild-type Nef 
and Nef with indicated point mutations. Upper panel, viral replication was gauged from levels of 
reverse transcriptase (RT) activity in culture supernatants. Lower panel, MIP-1 levels were 
determined by ELISA (Jacque, Unpublished data).   
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production than the ΔNef virus or mock infection. Similarly, all Nef mutant viruses were 
able to induce 9-fold to12-fold higher MIP-1 production than ΔNef virus. The 
corresponding mutated motifs appeared to be dispensable for chemokine induction by 
Nef. Therefore, we concluded that MIP-1 chemokine production can be induced by Nef 
independently of other classical Nef activities. 
The domain required for MIP-1 induction maps to a 31-amino acid 
region in HIV-1 NL4.3 Nef 
With the motifs responsible for other classical Nef functions excluded, it was speculated 
that Nef regulated MIP-1 chemkine production through some unknown motifs. To 
identify the possible motifs, we narrowed down the Nef region that was required for 
MIP-1 induction by deletion mutagenesis.  
To determine whether the functional motifs lay in the N or C-terminal half of the protein, 
a series of Nef truncations with successive 15 amino acid deletions up to 90 amino acids 
from either the N or C-terminus were constructed (Fig. 3-2). An HA tag was inserted at 
the C-terminus of the truncated proteins in order to facilitate their analysis by western 
blotting. The result shows that truncations of up to 30 amino acids from the N-terminus 
or up to 45 amino acids from the C-terminus were stably expressed but longer truncations 
were unstable.  To facilitate the analysis of unstable Nef mutants with longer truncations, 
GFP protein was fused to the C- terminus of Nef truncation mutants lacking 90 amino 
acids from either the N or the C-terminus (N90.GFP and C90.GFP, respectively).  
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Figure 3-2: Construction of Nef mutants containing stepwise 15-amino acid 
truncations from the N or C-terminus of HIV-1 Nef.  Expression of a series of Nef 
truncation mutants was evaluated by western blotting with an antibody directed to an HA-tag at 
the C-terminus of the Nef mutants.   
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These Nef-GFP fusions were next inserted into a macrophage-tropic ADA-ΔNef clone in 
the place of Nef (Fig. 2-1). The Nef-GFP fusion proteins lacking 90 amino acids from the 
N- or C-terminus were stably expressed (Fig. 3-3, lower panel). Monocyte-derived 
macrophages were infected with these recombinant viruses and culture supernatants were 
monitored at two- or three-day intervals for the presence of viral replication by RT and 
the level of MIP-1 by ELISA (Fig. 3-4). All recombinant viruses underwent a robust 
spreading infection in macrophage cultures and MIP-1 induction was evident in 
macrophages harboring a wild type Nef (Nef) or Nef fused to GFP at the C-terminus 
(Nef.GFP) (Fig. 3-4, left panels). There was no chemokine induction in macrophages 
infected with the virus lacking Nef (Nef) or in a virus harboring GFP in place of Nef 
(GFP).  Interestingly, chemokine induction was also evident in macrophages infected 
with HIV-1 variants harboring a 90 amino acid truncation at either the N or the C-
terminus (N90.GFP, C90.GFP, respectively) (Fig. 3-4, right panels).  Therefore, the 
first and last 90 amino acids of Nef appeared to be dispensable for the induction of 
chemokines in infected macrophages.  
Residues 91-116 in the conserved core region of Nef were the only sequences not 
affected by 90 amino acid truncations from the N- and C-terminus. To examine the role 
of this region in chemokine induction, 115 amino acids from the N- and C-terminus 
(N115, C115, respectively) were truncated and fused to GFP (Fig.3-4, upper panel).  
Additionally, an internal deletion (Nef85-115) removing 31 amino acids from the Nef 
core domain was constructed (Fig.3-3, upper panel). Stable expression of these Nef-GFP  
 
 
60 
 
    
Figure 3-3: Construction and expression analysis of Nef-GFP fusion proteins.  Upper 
panel, outline of Nef-GFP fusion constructs harboring 90 or 115 amino acid truncations 
from the N or C-terminus or harboring an internal 31 amino acid deletion.  Lower panel, 
expression of Nef-GFP truncation and deletion mutants was analyzed by western blotting 
with an anti-HA antibody. 
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Figure 3-4: Analysis of chemokine production in macrophages infected by HIV-1 
variants harboring wild-type Nef and truncation/deletion mutants with GFP fusion. 
Left panels, viral replication was gauged from levels of reverse transcriptase activity in 
culture supernatants. Right panels, MIP-1 levels were determined by ELISA.  Results 
are shown for macrophages cultures obtained from three independent donors. 
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fusions was confirmed by western blotting analysis (Fig.3-3, lower panel).  In contrast to 
viruses harboring 90 amino acid truncations at the N- or C-terminus of Nef, viruses 
harboring 115 amino acid deletions at the N- or C-terminus, or the virus containing a 31 
amino acid deletion between residues 84 and 116 of Nef, were unable to induce MIP-1 
(Fig. 3-4). This pattern was consistent in macrophage cultures prepared from three 
independent donors. These results demonstrated that a region located between residue 84 
and residue 116 of HIV-1 NL4.3 Nef was necessary for MIP-1β chemokine induction.   
The KEK motif is responsible for MIP-1 chemokine induction in HIV-
1 infected macrophages.  
Both HIV-1 Nef and SIV Nef induce chemokine production in infected macrophages 
(239), suggesting the presence of a functional motif that is common to HIV-1 and SIV 
Nef proteins. Alignment of the HIV-1 NL4.3 Nef region required for chemokine 
induction with the analogous sequences of SIVmac239 Nef revealed some candidate 
motifs (Figure 3-5). We focused our analysis on two motifs, K92EK and R105R, since 
these are predicted to be surface residues with the potential to interact with cellular 
factors (63, 66). Nef mutants with alanine substitutions at K92EK (K92EK/3A) and R105R 
(R105R/AA) motifs were inserted into HIV-1 ADA-ΔNef and examined for the ability to 
induce MIP-1 in infected macrophage (Fig. 3-6). Chemokine induction by the virus 
expressing wild-type Nef and the virus lacking functional R105R motif (R105R/AA) were 
indistinguishable (Fig. 3-6).  In contrast, MIP-1 levels in macrophage cultures infected 
with the Nef mutant lacking the K92EK motif (K92EK/3A) were indistinguishable from  
 
 
63 
 
 
 
Figure 3-5: Alignment of HIV-1 NL4.3 and SIVmac239 Nef sequences.  Common 
residues are shown in blue and motif candidates with predicted surface accessibility in 
green. Corresponding consensus sequences in different HIV-1 and SIV clades are listed 
in the box.  
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Figure 3-6: Identification of the K92EK motif within HIV-1 Nef as the determinant 
for MIP-1β induction in infected macrophages. Upper panel, viral replication and 
MIP-1 production in macrophages infected with viruses harboring wild-type Nef and 
Nef variants containing amino acid substitutions in the core domain of Nef.  Results are 
shown for macrophages from three independent donors. Lower panel, expression levels 
of Nef alleles harboring the indicated alanine substitutions was confirmed by western 
blotting. 
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macrophages infected with a Nef virus (Fig. 3-6).  Consistently, this pattern was 
observed in macrophage cultures derived from three independent donors. Therefore, we 
conclude the K92EK of HIV-1 NL4.3 Nef represents a functional motif that is responsible 
for MIP-1 induction. Furthermore, the KEK motif seems to be well conserved in most 
clades of HIV-1 and SIV (Fig. 3-5), and more importantly, when the KEK motif in 
SIVmac239 Nef was substituted with alanines, MIP-1 production was also impaired 
relative to virus harboring a wild-type SIV Nef in HIV-1 infected macrophages (Fig. 3-7). 
These further underscored a critical role of the KEK motif in chemokine induction by 
distinct Nef alleles. 
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Figure 3-7: Role of the KEK motif in chemokine induction by SIV Nef. Macrophages 
were infected with HIV-1 viruses expressing wild-type SIVmac239 Nef or SIVmac239 
KEK mutant. Viral replication and MIP-1 production were measured by RT assay (left 
panel) and ELISA (right panel), respectively. 
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Discussion 
In this chapter, we reported the identification of a novel functional motif KEK in HIV-1 
and SIV Nef that was responsible for induction of chemokine MIP-1β in infected 
macrophages. The mutagenesis analysis, which led us to the location of this motif, was 
carried out in three stages. 
 In the first stage, we tested five previously reported Nef point mutations including G2/A, 
P122D/AA, L164L/AA, E62EEE/4A and P72XXP/2A for their ability to regulate chemokine 
induction in HIV-1 infected macrophages. The results showed that all the mutants were 
as functional as the wild-type Nef in terms of MIP-1β induction, thus indicating these 
mutated motifs were not responsible for chemokine induction. These motifs have been 
shown to be required for classical Nef functions including down-regulation of CD4 and 
MHC-1, enhancement of virus infectivity and interaction with cellular kinases, which 
represent the most fundamental cellular activities currently known about the Nef proteins. 
However, exclusion of these motifs may have some implications in the exact mechanism 
of Nef-induced chemokine induction.  
The N-termianl G2 of HIV-1 Nef is the myristoylation site, which is strictly required for 
membrane targeting of Nef. The G2/A mutation which prevents myristoylation has been 
shown to impair most Nef functions. Interestingly, the G2/A mutant was still highly 
active in MIP-1β induction and the production induced by G2/A was indistinguishable 
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from that by wild-type Nef. Thus, myristoylation and membrane attachment may be 
dispensable for chemokine induction by Nef. This is supported by the results from other 
studies showing that unmyristoylated Nef induces chemokines in macrophages (197). 
Although about 30% of myristoylated Nef is attached to the plasma membrane, a large 
pool of Nef is present abundantly in the cytoplasm of infected cells. However, 
contribution of this cytoplamic Nef population to the cellular functions of Nef has been 
largely ignored. Our results from the G2/A mutant provide new evidence for possible 
cellular activities of cytoplasmic Nef, perhaps by manipulating cellular signaling 
pathways.  
The motif critical for HIV-1 Nef to form dimers was mapped to P122D (90). Mutation of 
this motif abolished CD4 and MHC-1 downregulation as well as the infectivity 
enhancement by Nef, suggesting that dimerization of Nef was important for these Nef 
activities. In contrast, chemokine induction by Nef was independent of the dimer form of 
Nef, since the P122D/AA mutant induced a high level of MIP-1β production. Together 
with the information from the G2/A mutant, this may suggest a flexible structural 
requirement for Nef to induce chemokines in infected macrophages.   
Nef down-regulates CD4 and MHC-I by different mechanisms. In the case of CD4, Nef 
mediates the internalization and degradation of cell surface CD4 molecules by directing 
them to the clathrin adaptor AP-2 (63, 85, 86). Nef induces MHC-I down-regulation 
through the PACS-dependent sorting pathway. The Nef mutant L164L/AA loses its 
association with AP-2, while the E62EEE/4A fails to bind to PACS-2 (85, 95), and thus 
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are defective in CD4 and MHC-I down-modulation, respectively. The ability of these two 
mutants to induce MIP-1β production indicates that the Nef-mediated lysosome or 
endosome pathways are uncoupled from Nef-induced chemokine induction.  
In the case of MHC-I down-regulation, Nef binds PACS-2 through the E62EEE motif and 
the complex triggers a multi-kinase cascade that eventually accelerates MHC-I 
endocytosis. In this signaling pathway, Nef needs another motif P72XXP to bind and 
activate SFK in TGN and initiates signal transduction (95). In fact, this proline-rich motif 
also mediates the interaction between Nef and intracelluar kinases such as Pak2 and Hck. 
In a multi-protein signalosome that also contains Rac, Cdc42 and Vav1 (240), Nef 
activates Pak2, which mediates downstream effects. Phosphorylation of at least one 
substrate kinase merlin, a key signaling molecule, by the Nef-Pak2 complex has been 
confirmed in primary T cells (241). Therefore, the asscociation of Nef with Pak2 appears 
to be central to alter signaling pathways in T cell activation (242). Similarly through the 
P72XXP motif, Nef tightly binds Hck, a Src family kinase primarily expressed in cells of 
macrophage lineage. The biological significance of the interaction between Nef and Hck 
in macrophages is unclear. It has been shown to negatively regulate cell surface 
expression of the MCSF receptor Fms on macrophage (243) as well as to promote 
fibroblast transformation (244). However, there is relatively little evidence for an 
essential role of the Nef-Hck interaction in priming macrophage activation. In monocytic 
cell lines, constitutive production of active transcription factor AP-1 by Nef appears to be 
dependent on the MAPK pathway and can be blocked by expressing dominant-negative 
Hck, suggesting that the Nef-Hck interaction may trigger signaling events via the MAPK 
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pathway that leads to AP-1 induction in macrophages (245). Therefore, it was tempting to 
speculate that the Nef-Hck interaction might be responsible for the Nef-dependent 
chemokine induction in macrophages. Our results, however, clearly demonstrate that the 
P72XXP/AA mutant defective in Hck interaction still remains fully active for MIP-1 
induction, which excludes the possibility that chemokine induction by Nef in 
macrophages is solely dependent on its interaction with Hck. More importantly, it 
indicates unknown signaling molecules other than Hck that Nef might target for signal 
transduction in infected macrophages.  
In the second stage, we utilized a progressive truncation strategy to identify the region 
that harbored the determinant for chemokine induction in Nef.  We initially constructed a 
series of 15-amino acid deletions at both the N- and C-terminus of HIV-1 NL4.3 Nef. 
Analysis of these mutants was hampered by the fact that deletions of more than 30 amino 
acids from the N-terminus or more than 45 amino acids from the C-terminus resulted in 
truncated mutants with undetectable expression level due to poor stability. This finding is 
consistent with the previous work of others indicating that the N- and C-terminal regions 
of Nef are critical to stabilize Nef structure (132, 142, 246). Importantly, our result 
further defined the truncation limits in both terminal regions of Nef that can be tolerated 
for stable expression. The regions, aa30-45 in the N-terminus and aa 45-60 in the C-
terminus, appeared to be critical, since mutants with truncations in these regions were 
unstable. The importance of these regions in structural stablization is supported by Nef 
structures shown in NMR and crystallography. Most of the N-terminus of Nef does not 
have a folded structure. Nevertheless, there is a well-defined short -helix between 
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Arg35 and Gly44 that is further stabilized by myristoylation (64). Our results of the 
unstable N-terminal truncation mutants, along with others (38, 84), underscore an 
important role for this -helix in Nef stability. In additon, our results from the unstable 
C-terminal truncation mutants are perfectly consistent with the previous work in which 
HIV-1 SF2 Nef was shown to lose stability when more than 40 amino acids were deleted 
from the C-terminus (142). Unlike the N-teriminal aa30-45 region with -helical 
structure, the aa45-60 region in the C-terminus was actually located in a flexible loop. 
Therefore, mutation in this region should not impair the general structural organization of 
Nef.  An alternative explanation might be the internal PEST-like sequences in Nef that, in 
the C-terminal truncated mutants, moves closer to the C-terminus and thus may direct the 
truncated products for premature degradation (247). 
The GFP fusion facilitates further analysis of unstable truncated Nef mutants that have 
large deletions in the N- and C-termini. Other groups have utilized the GFP fusion 
strategy to study the localization of Nef under distinct circumstances and it has been 
confirmed that fusing Nef at the C-terminus with GFP helps to avoid artificial 
localization of the Nef fusion proteins (80, 242, 248). As expected, N90.GFP and 
N115.GFP were present exclusively in the cytoplasm due to the abscence of plasma 
membrane targeting sequence, whereas C90.GFP and C115.GFP were localized to the 
cell membrane but also abundant in the cytoplasm (Dai, unpublished data). It should be 
noted that N90.GFP and C90.GFP both actively induced MIP-1 in macrophages 
despite the difference in localization. This is consistent with the result obtained with the 
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G2/A Nef mutant and further confirms the role of the cytoplamic pool of Nef proteins in 
chemokine induction.   
Furthermore, GFP fusion stabilized the truncated Nef mutants and thus significantly 
enhanced the expression of Nef.GFP fusion proteins as confirmed by western blotting 
analysis. However, relatively lower expression of N90.GFP and N115.GFP than others 
indicated that the N-terminus of Nef was a more critical structural determinant than the 
C-terminus (Fig. 3-3). Interestingly, N90.GFP, although expressed at a lower level than 
C115.GFP, was able to induce a significantly higher level of MIP-1 production. 
Therefore, it was the Nef determinant within the deletion region, rather than the 
expression level, that regulated the chemokine induction in macrophages. In addition, it 
has been demonstrated that the Nef.GFP fusion protein is defective in Pak-2 activtition 
(249), and since we have shown in our study that Nef.GFP was fully functional in MIP-
1β induction, this gives another line of evidence, in addition to the ability of the 
P72XXP/2A and R105R/AA mutants to induce MIP-1β, which indicates that Pak-2 
activation is not involved in chemokine induction by Nef.  
In the last stage, we introduced point mutations into two candidate motifs including 
K92EK and R105R, within the Nef region that was indispensable for chemokine induction 
and identified K92EK as the functional motif. The selection of these candidates was based 
on two conditions. Firstly, they are all conserved residues in HIV-1 and SIV Nef. Since 
SIV Nef has been shown to induce MIP-1 as well (198), we were most interested in 
motifs consisting of residues common to HIV-1 and SIV Nef. In addition, most of these 
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motifs, according to Nef structural analysis, are proposed to have surface accessibility for 
potential interaction with cellular proteins (63, 66). This is important because Nef itself 
has no known enzymatic activity, and therefore signaling pathways triggered by Nef most 
likely involve its interaction with cellular proteins. Indeed, the R105R motif has been 
reported to be responsible for such Nef activities. Nef must have an intact R105R motif to 
bind and activate Pak-2 (143). Our result showed the R105R/2A mutant was fully 
functional for MIP-1β induction, which also supports the idea that Nef induces 
chemokines in HIV-1 infected macrophages independently of other biological activities. 
Among all the point mutants we tested, K92EK/3A consistently failed to induce MIP-1β 
production in macrophages cultures prepared from three independent donors. Notably, 
alanine substitution of the corresponding KEK residues in SIVmac239 Nef also impaired 
its ability to induce MIP-1β production and the KEK motif is highly conserved in distinct 
Nef isolates from HIV-1 and SIV clades, suggesting KEK motif-dependent chemokine 
induction may represent a conserved critical function of SIV and HIV-1Nef in 
macrophages. 
In our experiments, wild-type Nef or Nef mutant proteins were expressed endogeneously 
in the context of viral infection. We collected supernatants at various time points to 
monitor viral replication and chemokine production. Interestingly, by comparing the 
curves of viral replication and corresponding chemokine production, it appeared that the 
peak of the MIP-1β chemokine induction usually correlated with that of the viral 
replication. In some donors, the chemokine curves reached the peaks even two or three 
days later than the viral replication curves. In addition, in some experiments when 
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macrophages failed to support spreading infection, MIP-1β was not detected even for the 
wild-type virus (Dai, unpublished data). These results indicate that Nef-induced 
chemokine production is viral replication dependent, which is supported by another study 
showing that inactivated, noninfectious virus particles do not induce chemokine secretion 
from DCs (198).  
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Chapter IV.  
Impact of the K92EK/3A mutation on distinct Nef 
functions  
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Abstract 
By mutagenesis analyses, we identified the KEK motif in Nef as the determinant that 
regulated MIP-1β chemokine production by HIV-1 infected macrophages. This novel 
motif had not been linked to any other Nef activities. Thus, it remained to be elucidated 
whether mutations in the KEK motif affected other Nef functions. In this chapter, we 
attempted to examine the cellular effects of the HIV-1 Nef mutant K92EK/3A in terms of 
1) down-regualtion of CD4 and MHC-I; 2) induction of secretory factors; 3) 
neurotoxicity; and 4) enhancement of virus infectivity. The K92EK/3A mutant exhibits 
normal down-regulation of both CD4 and MHC-I molecules. In the supernatant from 
macrophages infected by K92EK/3A mutant virus, the production of several other 
regulatory factors such as MIP-1, IL-6, IL-16 and ferritin was also impaired. The 
conditioned macrophage supernatants from K92EK/3A mutant virus infection exhibited 
less neuronal toxicity than that from wild-type virus infection. Finally, the K92EK/3A 
mutant had no significant effect on virus infectivity in macrophages and PBLs. These 
results suggest a specific role of the KEK motif in Nef functions that may contribute to 
viral replication and pathogenicity.  
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Introduction 
In infected macrophages, Nef induced chemokine production in a way that appeared to be 
independent of other cellular activities of Nef, as suggested by the normal MIP-1 level 
induced by Nef point mutants defective in other Nef functions (Fig.3-1). The mutagenesis 
analyses identified the Nef mutant motif K92EK/3A that is defective for MIP-1 
induction in infected macrophags. We have demonstrated that the K92EK/3A mutant 
appeared to be as stable as the wild-type Nef by western blotting analysis (Fig. 3-6). 
However, it is still possible that mutations in KEK motif leads to a global impact on Nef 
that may impair all cellular activities of Nef, which may not be detected simply by 
western blotting analysis. In this chapter, we aimed to determine how mutations in the 
KEK motif influence other Nef activities. 
Although the down-modulation of CD4 and MHC-I molecules are two independent 
activites of Nef, they generally represent the hallmark cellular activities of Nef. Their 
mechanisms are relatively well established and a few defective Nef mutants in these 
functions have been described. Mutations in L164L and E62EEE lead to specific functional 
loss of CD4 and MHC-I downregulation, respectively. In contrast, mutations in G2 and 
P122D impair these Nef functions in a non-specific way that also affects other Nef 
functions as well. Although Nef mutants L64L/2A and E62EEE/4A exhibit full activity for 
MIP-1 induction indicating that CD4 and MHC-I downregulation were not required for 
chemokine induction, it was also important to address whether the K92EK/3A mutant 
defective in chemokine induction was still functional in CD4 and MHC-I down-
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regulation. 
We have shown that the KEK motif was indispensable for MIP-1 induction in 
macrophages. In those experiments, we measured MIP-1 as the major standard for the 
ability of Nef or Nef mutants to induce cytokine/chemokine. In fact, the CC-chemokine 
MIP-1 is just one of the secretory molecules in the supernatant of infected macrophages. 
Upon HIV-1 infection, macrophages become an active stage for Nef activities and 
eventually alter the cellular environment of infection sites by releasing a wide range of 
factors such as MCSF, TNF-, IL-6, IL-16, MIP-1, MIP-, sCD23, sICAM and ferritin. 
While the presence of MIP-1, MIP-1, sCD23 and sICAM appears to favor viral 
replication and dissemination, dysregulated expression of MCSF, TNF-, IL-6, IL-16 
and ferritin may contribute to HIV-1 pathogenesis in specific cells and tissues. In this 
chapter, we determined the presence of MCSF, TNF-, MIP-1, IL-6, IL-16 and ferritin 
in infected macrophages and examined whether their production was also regulated by 
the KEK motif of Nef.  
HIV-associated dementia (HAD), caused by abnormal neuroinflammation and 
subsequent cell death of neuronal cells, is a common neurological disorder in AIDS 
patients (250, 251). Nef is considered one of the viral proteins that contribute to the 
pathogenesis of HAD (252, 253). The expression of Nef is abundant in astrocytes, which 
appears to be linked to neuroinflammtion (252, 254). Nef has been shown to recruit 
leukocytes into the central nervous system (CNS) (227). Although rNef itself is toxic to 
neurons, secretion of a large amout of Nef proteins in vivo is still questionable. However, 
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the endogenous expression of Nef in astrocytes has been shown to induce cytokines and 
chemokines that may be toxic to neurons (230, 255), probably by manipulating cell 
signaling pathways. This indicates an indirect Nef-mediated killing effect on neurons. In 
this chapter, some evidence will be presented to show that Nef induces neurotoxins in the 
supernatants of Nef-expressing macrophage. Furthermore, we also evaluated the impact 
of mutations in the KEK motif on this Nef-mediated neuronal cell death effect. 
The function of Nef to enhance virus infectivity is not fully understood. It is generally 
accepted that this function requires the presence of Nef in virus-producing cells rather 
than in the target cells (113-115). Importantly, it has been shown that co-expressing Nef 
in trans can restore the impaired infectivity of Nef-deficient virus (113, 115), but the 
essential compensation made by Nef for the intrinsic property of infectious virions 
remains unclear. Recently, a cellular factor dynamin2 (Dyn2) has been identified as the 
binding partner of Nef that is required for enhancement of virus infectivity, but the 
mechanism has not been elucidated (134). In this chapter, we examined the ability of the 
K92EK/3A mutant to enhance virus infectivity as well as its association with cellular 
Dyn2 by co-immunoprecipitation.  
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Result 
The KEK motif is dispensable for down-regulation of CD4 and MHC-I 
Down-regulation of cell surface CD4 and MHC-I molecules is one of the most studied 
activities of Nef. Domains within HIV-1 NL4.3 Nef such as L164L, E62EEE that 
independently regulate CD4 and MHC-I down-modulation are not required for MIP-1β 
induction (Fig. 3-1). We next examined whether mutagenesis of the K92EK motif 
impaired the ability of Nef to promote down-regulation of CD4 and MHC-I molecules. 
To this end, Jurkat Tag cells that have both cell surface CD4 and MHC-I were co-
transfected with plasmids expressing wild-type or mutant Nef proteins as well as a GFP 
expression vector (Fig. 4-1). We compared the activity of the K92EK/3A mutant to a 
W57L/AA Nef mutant that has been previously shown to inactivate Nef-dependent CD4 
down-regulation as well as an E62EEE/4A mutant that abrogates Nef-dependent MHC-  
down-regulation (83, 93). As expected, the W57L/AA Nef mutant was specifically 
impaired for CD4 down-regulation yet retained the ability to down-regulate MHC- I and 
conversely, the E62EEE/4A Nef mutant retained the ability to down-regulated MHC-I 
but lacked the ability to down-regulate CD4. Compared to mock controls, wild-type Nef 
significantly down-regulated both CD4 and MHC- expression on cell surface, and more 
importantly the K92EK/3A mutant similarly down-regulated both CD4 and MHC- as 
well. Therefore, the KEK motif is dispensable for CD4 and MHC- down-regulation by 
Nef.  
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Figure 4-1: The K92EK motif in HIV-1 Nef is dispensable for CD4 and MHC- 
down-regulation.  Jurkat Tag cells were co-transfected with SRα plasmids expressing 
the indicated Nef alleles and a GFP expression vector at a molar ratio of 3:1. After 24 h, 
transfected cells were stained for cell surface CD4 or MHC- and analyzed by FACS.  
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Release of other factors by macrophages, in addition to MIP-1β, also 
requires the KEK motif of Nef 
We observed the Nef-dependent MIP-1 induction in infected macrophages and 
identified the KEK motif as the determinant of Nef-dependent MIP-1 induction. 
However, previous studies have demonstrated that a variety of factors, in addition to 
MIP-1, are also induced in infected macrophages and DCs, for example, MCSF, TNF-α, 
MIP-1α, IL-6, IL-16 and ferritin  (1, 178, 198) (Swingler, unpublished data). We 
examined the presence of these molecules in the supernatants of infected macrophage 
cultures and determined the correlation of their induction with Nef expression and the 
KEK motif. To this end, we infected macrophages with viruses expressing no Nef (ΔNef), 
wild-type Nef (Nef) or the K92EK/3A mutant (K92EK/3A) and measured the expression 
level of each factor by ELISA (Fig. 4-2). As a reference, production of MIP-1 was Nef-
dependent and was significantly reduced in the supernatants of macrophages infected by 
the K92EK/3A virus. The same pattern was observed for MIP-1 production. We also 
detected the presence of IL-6 and IL-16, but at a much lower level compared to MIP-1 
and MIP-1. However, their induction by wild-type Nef virus was still higher than that 
by ΔNef or KEK92/3A mutant virus. In contrast, a large amount of MCSF production was 
induced independently of Nef expression or the KEK motif, which is consistent with our 
previous data showing that MCSF induction required the viral envelope glycoprotein and 
was Nef-independent (256, 257). Although TNF-α induction by Nef was reported by 
other groups (197, 198), 
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Figure 4-2: Advanced analysis of chemokine and cytokine production induced by 
the K92EK/3A mutant. Macrophages were infected with HIV-1 viruses with no Nef, 
wild-type Nef and K92EK/3A mutant. The production level of each factor was determined 
by ELISA and viral replication was gauged from levels of reverse transcriptase activity in 
supernatants of macrophage cultures.   
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Figure 4-3: The KEK motif is required for Nef-dependent ferritin release from 
macrophages. Ferritin concentrations were measured by ELISA in the supernatants of 
macrophages expressing wild-type HIV-1 Nef, no Nef or KEK mutant and mock-infected 
macrophages (Swingler, unpublished data) . 
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we only observed a background level of TNF-α production and no correlation with the 
Nef expression or the KEK motif. Furthermore, we examined the ferritin realease in 
macrophage supernatants and found that macrophages expressing Nef but not the 
K92EK/3A mutant produced elevated levels of ferritin relative to ΔNef virus or mock 
infected macrophages (Fig. 4-3). 
Supernatants of macrophages infected with viruses expressing wild-type 
Nef but not the K92EK/3A mutant induce neuronal apoptosis  
HIV-1 infection of macrophages leads to the release of soluble factors in supernatants 
that may have neurotoxic activities (258, 259). To determine whether Nef induces 
secretion of neurotoxins from infected macrophages, we initiated spreading infection in 
macrophages with ADA or ADA-Nef viruses, and mock-infected cells as control. We 
harvested supernatants from infected macrophages and monitored RT activity and MIP-
1 production. NT2.N neuronal cells were incubated with the conditioned macrophage 
supernatants for 48 hours then neuronal apoptosis was evaluated by the Caspase-Glo 3/7 
assay. As expected, both ADA and ADA-Nef viruses were able to initiate spreading 
infection in macrophages (Fig. 4-4, upper panel), but MIP-1 induction was only evident 
in supernatants from ADA but not ADA-Nef infected macrophages (Fig. 4-4, upper 
panel), which was also an indicator of Nef-dependent production of secretory factors in 
the supernatants. Importantly, neuronal cells displayed more severe cell death when  
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Figure 4-4: Induction of neurotoxicity in macrophage supernatants by Nef. 
Macrophages were infected with ADA, ADA-ΔNef or mock-infected. Supernatants were 
collected at indicated time points. Upper panel, RT activity and MIP-1β production in the 
supernatants were measured to monitor viral replication and release of secretory factors, 
respectively. Lower panel, the collected macrophage supernatants were used to treat 
neuronal cells for 48 hours and induction of cell death was determined by Caspase-Glo 
3/7 assay (Lower panel: Stranska, unpublished data). 
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incubated with conditioned supernatants from ADA infected macrophages than those 
treated with supernatants from ADA-Nef or mock-infected macrophages (Fig. 4-4, 
lower panel). Interestingly, neuronal cell death caused by the supernatants derived from 
ADA- infected macrophages appeared to correlate with MIP-1 levels in the supernatants. 
Nevertheless, immunodepletion of MIP-1 did not inhibit neurotoxic activity of the 
supernatants (Stranska, unpublished data), indicating that an unknown neurotoxin was 
induced by Nef. We then examined whether mutations in the KEK motif impaired Nef-
mediated neurotoxicity (Fig. 4-5). The results showed that the K92EK/3A mutation 
significantly reduced neuronal apoptosis induced by the conditioned macrophage 
supernatant by 64% compared to wild-type Nef (P<0.001). Therefore, the KEK motif is 
also a major contributing factor in Nef-induced neurotoxicity. 
The K92EK/3A mutation has no significant effect on virus infectivity in 
macrophages and PBLs.  
The molecular basis for infectivity enhancement by Nef remains unclear and is also 
complicated by the fact that viruses harboring Nef mutations in distinct functional motifs 
may present partial or full infectivity loss. We have demonstrated that the K92EK/3A 
mutant was defective in chemokine induction yet was still able to down-regulate both 
CD4 and MHC-I, indicating that mutagenesis of the KEK motif did not result in global 
destruction of Nef functions. We next examined how mutations in the KEK motif affect 
virus infectivity in macrophages and PBLs by taking advantage of an HIV-1 reporter 
proviral clone NL4-3.Luc.R-E-. This clone is Nef-deficient with a luciferase gene in the   
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Figure 4-5: Reduced induction of neurotoxicity in macrophage supernatants by the 
K92EK/3A mutant. Neuronal cells were cultured with conditioned supernatants from 
macrophages infected with viruses harboring Nef and Nef mutants or mock-infected 
macrophages. 48 hour later, cell death in neuronal cells was determined by Caspase-Glo 
3/7 assay. (Stranska, unpublished data)  
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position of Nef. The envelope gene is also mutated with a frameshift, and thus expression 
of X4- or R5- envelope proteins must be provided in trans. Therefore, luciferase 
expression indicates a single-round infection. By co-expressing wild-type Nef or the 
K92EK/3A mutant in trans, we were able to evaluate their influence on virus infectivity in 
macrophages and PBLs.  
To infect macrophages, reporter viruses were complemented with M-tropic envelope, as 
well as wild-type Nef or the K92EK/3A mutant, with or without VSV-G pseudotyping, 
and luciferase activity was measured 48 hour post infection. Based on the levels of 
luciferase expression, macrophage infection initiated by all three non-pseudotyped 
viruses was at a similar low level and no enhancement of virus infectivity promoted by 
wild-type Nef or the K92EK/3A mutant was observed (P>0.05) (Fig.4-6, left panel). The 
same viruses, when tested in TZM-bl cells, were highly infectious. However, the 
infectivities of the viruses complemented with or without wild-type Nef were not 
statistically different (P>0.05) and the K92EK/3A mutation exhibited no significant effect 
on virus infectivity compared with wild-type Nef and no Nef expression (P>0.05) (Fig. 4-
6, right panel). Therefore, we conclude that K92EK/3A mutant has no significant effect on 
virus infectivity in macrophages. 
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Figure 4-6: Infectivity analysis of ADA-ΔNef complemented with in trans expression 
of Nef or the K92EK/3A mutant in macrophages. Reporter viruses NL4-3.Luc.R-E- 
were complemented with M-tropic envelope and wild-type Nef or KEK mutant, with or 
without pseudotyping with VSV-G. Same amount of viruses normalized by RT were used 
to inoculate macrophages (left panel) and TZM-bl cells (right panel) for 2 hour and virus 
infectivity was measured 48 hour post-infection. The results are presented as luciferase 
activity quantified by the bright-glo assay system. 
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We then conducted a similar experiment by complementing reporter viruses with T-tropic 
envelope and examined virus infectivity in PBLs by measuring luciferase signals. Similar 
to the results from the infecticity assay in macrophages, T-tropic viruses complementing 
with no Nef, wild-type Nef and the K92EK/3A mutant exhibited no significant difference 
in virus infectivity in PBLs (P>0.05) (Fig. 4-7, left panel). The virus infectivities, when 
tested in Ghost cells, were also statistically indistinguishable (P>0.05) and the K92EK/3A 
mutation had no significant effect on virus infectivity compared with wild-type Nef 
(P>0.05) (Fig. 4-7, right panel). In addition, all three viruses showed indistinguishable 
infectivities independently of Nef expression when they were pseudotyped with VSV-G 
(P>0.05) (Fig. 4-6, 4-7). 
Collectively, we conclude that the K92EK/3A mutation has no significant effect on virus 
infectivity in macrophages and PBLs.  
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Figure 4-7: Infectivity analysis of ADA-ΔNef complemented with in trans expression 
of Nef or K92EK/3A mutant in PBLs. Reporter viruses NL4-3.Luc.R-E- were 
complemented with T-tropic envelope and wild-type Nef or KEK mutant, with or without 
pseudotyping with VSV-G. Same amount of viruses normalized by RT were used to 
inoculate PBLs and Ghost cells and virus infectivity was measured on day 6 and day 2 
post infection, respectively. The results are presented as luciferase activity quantified by 
the bright-glo assay system. 
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Discussion 
In this chapter, we presented the results of a comprehensive functional assessment of the 
HIV-1 Nef K92EK/3A mutant defective in MIP-1β induction.  
The K92EK/3A mutant remained highly active for CD4 and MHC-I modulation, the two 
classical functions of Nef. This fully uncoupled the molecular basis for Nef-induced cell 
surface molecule down-regulation from that of Nef-regulated chemokine induction. More 
importantly, it suggests that the defect of the K92EK/3A mutant in chemokine induction 
was not due to a destructive effect on global Nef functions.  
The Jurkat Tag cell line made it possible to test both CD4 and MHC-I down-regulation 
by Nef in one cell culture system. The cells had abundant CD4 and even higher MHC-I 
expression on the cell surface that were efficiently down-regulated upon Nef expression. 
Although we gated on the GFP positive population that represented the transfected cells 
to monitor the down-regulation effect, it should be noted that this down-regulation effect 
also appeared evident in GFP negative cells as well. This is due to the molar ratio of the 
co-transfected plasmids and the high efficiency of the nucleofection method. Since we 
co-transfected three fold more Nef or Nef mutant-expressing vectors than the GFP-
expressing vector and since more than 70% cells were GFP positive, it was not suprising 
that almost all of the transfected cells were expressing Nef. 
Although mutagenesis of the KEK motif did not affect Nef-induced CD4 and MHC-I 
down-regulation, it impaired the induction of several other secretory factors such as MIP-
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1 α, IL-6, IL-16, ferritin as well as possible unknown neurotoxins in macrophage 
supernatants. The spontaneous Nef-dependent induction of MIP-1α and MIP-1β is 
consistent with the previous data from the macrophage infection experiments (1). In 
different donors, the induction patterns of MIP-1α and MIP-1β appeared to be the same, 
which was characterized by two concentration curves that displayed very similar trends 
during macrophage infection. The MIP-1α and MIP-1β curves seemed to correlate with 
the RT curves and reached their peaks at the same time. Indeed, the induction of MIP-1α 
and MIP-1β was dependent on viral replication especially during spreading infection in 
macrophages. One possible explanation would be that Nef expression had to be 
accumulated to a threshold to trigger chemokine induction. In agreement with this, the 
intracellular concentration of Nef in T cells has been described to dictate whether CD4 
and
 
MHC-I molecules are down-regulated or T cell activation is affected (260).
 Although 
Nef is one of the viral proteins that are expressed at early stages of infection, its 
expression level can be also limited by infection efficiency. In macrophage infection 
experiments where virus replicated in a spreading manner, the number of initially 
infected macrophages was so limited that Nef expression was undectable by western 
blotting analysis in macrophgaes lysates for the first several days (Dai, unpublished data). 
With the viral replication proceeding, Nef expression was accumulated in more and more 
infected macrophages and finally reached a possible threshold for MIP-1α and MIP-1β 
induction. Furthermore, mutagenesis of the K92EK motif significantly reduced MIP-1α 
and MIP-1β induction to a similar extent. Therefore, Nef may need the KEK motif for the 
same pathway to regulate both MIP-1α and MIP-1β production.  
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In addition to MIP-1α and MIP-1β, we examined the release of other factors during HIV-
1 infection in macrophages. Our data suggested that the induction of IL-6, IL-16 and 
ferritin from macrophage supernatant was also regulated by Nef, which is consistent with 
studies demonstrating the increased induction of these factors by Nef in a variety of cell 
types including monocyte, DCs, macrophages, astrocytes and microglial cells (197, 198, 
230, 261). Importantly, we found that regulation of IL-6, IL-16 and ferritin release also 
required the KEK motif. The expanded list of the KEK motif-dependent molecules may 
suggest a specific role for this motif in switching on the dysregulated release of a broader 
panel of regulatory factors, which may contribute to HIV-1 replication and pathogenesis.   
Unlike MIP-1α and MIP-1β, IL-6 and IL-16 exhibited totally different production curves. 
Specifically, induction of IL-6 arose at the early stage of the infection prior to the RT 
peak. In contrast, induction of IL-16 appeared to drop between two peaks at both the 
early and the late stage of the infection. Other studies confirm that IL-6 is induced early 
after HIV monocytic infection (262, 263). Since IL-6 is potent activator of C/EBP, it can 
activate other cytokine genes such as IL-1β (264) and TNF- (265). Although we did not 
detect potent IL-1β or TNF- induction in our experiments probably due to the low level 
of IL-6 induction itself, this still raises the possibility that early cytokines/chemokine 
induced by Nef may have regulatory effect on late induced cytokines/chemokine. If this 
is true, Nef may regulate complicated cytokine/chemokine networks in infected 
macrophages, although it is still unclear whether Nef requires the KEK motif to activate 
single or multiple pathways to induce the production of these molecules. 
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In our macrophage infection experiment, we found a much lower level of IL-6 induction 
and did not consistently observe Nef-dependent production of IL-1β and TNF- as 
reported by another study in which macrophages were treated with recombinant Nef 
(197). The discrepancy may be a reflection of different mechanisms by which 
endogenously expressed Nef and extracellular rNef activate signaling pathways in 
macrophages. In the rNef system, macrophages are exposed to levels of Nef that are 
artificial and not achievable in vivo. Even if internalization of rNef occurs, the results 
may not represent physiological events induced by intracellular Nef in infected cells.  
Indeed, two motifs E
156
E and D
174
D have been reported to be required for extracellular 
recombinant Nef to induce MIP-1 and MIP-1. However, in our macrophage infection 
experiment, these two motifs appeared to be totally dispensable for MIP-1 and MIP-1 
induction in the context of viral infection (Fig. 4-8).  
We have demonstrated that Nef induced a wide range of factors in infected macrophage 
supernatants. In addition, we showed the exsistence of neurotoxic activity in the 
conditioned media from infected macrophage cultures. Neurotoxin induction appeared to 
be dependent on Nef and an intact KEK motif. Recently, it was reported that supernatants 
from Nef-expressing astocytes induced neuronal cell death which was linked to increased 
IP-10 expression (255). Unfortunately, IP-10 expression was not detectable in the 
supernatants of our macrophage experiments (Dai, unpublished data). Further studies are 
needed to reveal the exact identity of the neurotoxic factor(s) as well as the molecular 
mechanism by which they are regulated by the KEK motif of Nef. 
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Figure 4-8: The D174D, E156E motifs of HIV-1 Nef are dispensable for Nef-induced 
MIP-1β production in the context of macrophage infection. Macrophages were 
infected with viruses harboring wild-type Nef and Nef variants containing amino acid 
substitutions as indicated. Viral replication was determined by RT (upper panel) and 
MIP-1 production by ELISA (lower panel).  
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Nef is known to moderately enhance virus infectivity. However, we did not observe 
evident enhancement of virus infectivity by Nef in either macrophages or PBLs with our 
infectivity assay system. Furthermore, the K
92
EK/3A mutation exhibited no significant 
effect on virus infectivity. Therefore, the KEK motif does not seem to be the determinant 
of Nef for virus infectivity enhancement. In support of this, both wild-type Nef and the 
KEK mutant bind to Dyn2 (Fig. 4-9), which is required for Nef-dependent infectivity 
enhancement (134). A possible reason that they did not exhibit a significant boost effect 
on virus infectivity in our system is that the experimental conditions might not be optimal, 
since it has been shown that the boost effect on virus infectivity by Nef may vary 
depending on virus isolates and producer cell types (116, 266). SF2 Nef exhibited a more 
significant boost effect on virus infecticvity than NL4.3 Nef (116) and Jurkat T cells have 
been used as producer cells to observe significant infectivity enhancement (134). These 
can be utilized in future to optimize our infectivity assay system.   
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Figure 4-9: Both Nef and KEK mutant bind Dynamin2.  293T cells were transfected 
with SRα vectors expressing wild-type Nef and Nef mutant lacking the KEK motif that 
were double-tagged with HA and Flag on C-terminus. Anti-HA immunoprecipitates 
(IP) prepared from 293T cells lysates were analyzed by immunoblotting (IB) with anti-
Dyn2 and anti-Flag.  
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CHAPTER V. 
 FINAL CONCLUSION AND PERSPECTIVE 
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1. Summary  
The work presented in this thesis described the identification of a novel functional KEK 
motif within HIV-1 and SIV Nef proteins that is required for the induction of MIP-1 
production from infected macrophages. A series of Nef truncation mutants and various 
point-mutants were examined to establish that the conserved KEK domain of HIV-1Nef 
was responsible for MIP-1 production. Mutagenesis in the KEK motif also reduced the 
Nef-dependent induction of MIP-1α, IL-6, IL-16 and ferritin, as well as the release of 
neurotoxin in the supernatants of infected macrophages. However, mutation of the KEK 
motif did not impaired other general functions of Nef in terms of CD4 and MHC-I down-
modulation. In addition, mutation of the KEK motif had no significant effect on virus 
infectivity in macrophages and PBLs. Collectively, this thesis research revealed a specific 
determinant within Nef that might be critical for a central feature of HIV-1 replication 
and pathogenicity.  
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2. General discussions  
2.1. Involvement of Env in Nef-dependent MIP-1β induction 
In our macrophage infection experiments, we observed the reduced production of several 
factors in the supernatants of macrophages infected with the ΔNef or K92EK/3A mutant 
virus. However, it should be noted that in some donors they appeared to be slightly 
higher than the background of mock infection (Fig. 3-4, 3-5, 4-2, 4-8), which might 
indicate the involvement of other factors in cytokine/chemokine regulation during HIV-1 
infection.  
As discussed in chapter IV, we interpreted the correlation of MIP-1 and MIP-1 with 
viral replication as the accumulation of Nef expression. However, with more viral 
particles produced during infection, the accumulaton of viral envelope proteins should 
also be taken into consideration. In fact, studies have demonstrated the ability of 
recombinant HIV-1 gp120 to induce cytokines and chemokines (267). Thus, it is possible 
that Nef causes an indirect effect on cytokine/chemokine induction through Env. This 
model was attractive since it might also help to explain the mechanism of Nef-dependent 
infectivity enhancement.  
We tested this hypothesis by infecting macrophages with wild-type virus (WT), Nef-
deficient virus (ΔNef), Env-deficient virus (ΔEnv) and dual deficient virus (ΔNefΔEnv) 
that were pseudotyped with VSV-G (Fig. 5-1). As expected, ΔNef induced significantly 
less chemokine induction compared to WT. In contrast, MIP-1 production induced by  
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Figure 5-1: Involvement of Env in Nef-dependent MIP-1β chemokine induction. 
Macrophages were infected with with wild-type virus (WT), Nef-deficient virus (ΔNef), 
Env-deficient virus (ΔEnv) and dual deficient virus (ΔNefΔEnv) and all viruese were 
pseudotyped with VSV-G.  MIP-1β production in the supernatants was measured by 
ELISA. 
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ΔEnv was indistinguishable from that induced by WT. This excluded Env as a major 
determinant for MIP-1 induction. In addition, there was no synergistic reduction in 
MIP-1 production induced by ΔNefΔEnv compared to that induced by ΔNef (Fig. 5-1). 
Furthermore, we used anit-CD4 antibody and CCR5 antagonist TAK779 to block 
interaction between envelope and receptor and co-receptor, respectiviely, and neither 
seemed to affect Nef-dependent MIP-1 induction (Fig. 5-2). Collectively, these results 
did not seem to support the involvement of envelope proteins in Nef-induced MIP-1β 
chemokine production. However, we did not completely exclude involvement of other 
viral proteins such as Tat, Vpr that might also have the ability to induce cytokines and 
chemokines. Therefore, further studies are needed to determine whether Nef works by 
itself or with other viral factors to regulate cytokine/chemokine production. 
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Figure 5-2: Nef-induced chemokine production is independent of gp120 interactions 
with CD4 and CCR5. Macrophages were infected with VSV-G-pseudotyped wild-type 
virus (wt) and Nef-deficient virus (ΔNef) in the presence of an anti-CD4 antibody (upper 
panel) or a CCR5 antagonist TAK779 (lower panel).  
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2.2. Nef and CD40 signaling pathways  
While studies have provided a substantial amount of observations regarding Nef-induced 
cytokine/chemokine in macrophages, understanding of the signaling pathways that are 
involved is still very limited. CD40 is an important cell surface marker on macrophages 
and CD40-CD40L interaction is thought to play a physiological role in immune 
regulation of macrophages. CD40-induced activation of macrophages results in 
morphological changes and cytokine/chemokine secretions (231, 268). Although CD40 
itself does not harbor kinase acitivity, stimulating CD40 with CD40L activates a complex 
network of signal transduction pathways that involve various kinases and TNF-R 
associated factors (TRAFs). Activation of NF-B has been described as one major 
downstream effect of CD40-induced pathways (269). In the quiescent state, NF-B is 
predominantly present in the cytoplasm in association with its inhibitors IB - and IB-
. CD40-CD40L interaction triggers signals that lead to NF-B activation by releasing 
NF-B from IB inhibition. Once NF-B gets into nucleus as a transcriptional complex, 
it can recognize promoter sequences of cytokine/chemokine genes including IL-1, IL-6, 
IL-8, IL-10, IL12, TNF-, MIP-1, and MIP-1 and activate their expression (270-273). 
Therefore, it is possible that Nef may mimick or intersect the CD40 signaling pathways 
to alter cellular conditions such as NF-B activation in infected macrophages. In support 
of this, endogenous expression of Nef is sufficient to functionally substitute for CD40L 
stimulation to induce the production of sCD23, sICAM and ferritin by macrophages in a 
NF-B dependent manner (178, 231).  In addition, extracellular rNef induces the release 
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of IL-1, IL-6, TNF-, MIP-1, and MIP-1 by macrophages, which is also correlated 
with NF-B activation (197).  
To futher examine the relationship between Nef and CD40 signalling, we infected 
macrophages with VSV-G-pseudotyped HIV-1 viruses expressing no Nef (Nef), wild-
type Nef (Nef) or K92EK/3A mutant (K92EK/3A), and afterwards stimulated infected 
macrophages with CD40L (Fig. 5-3). MIP-1 induction was measured after viral 
infection as well as after CD40L stimulation. The rationale is that, if Nef occupies the 
only machinery in the CD40 signaling pathway that triggers MIP-1 induction, one 
should expect that CD40L simulation would induce less MIP-1 production by 
macrophages that have been infected with Nef-expressing viruses, because 
overexpression of Nef may have saturated the signaling pathway and weakened the 
subsequent MIP-1 induction by CD40L. However, expression of Nef did not seem to 
interfere with CD40L-induced MIP-1 production. The net amount of CD40L-induced 
MIP-1 production was close in all infected macrophages regardless of Nef expression. 
Thus, it is possible that CD40L stimulation triggers multiple parallel pathways that lead 
to NF-B activation and Nef might only intersect one or several specific pathways.  
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Figure 5-3: CD40L-induced MIP-1β production is not affected by Nef expression 
from previous viral infection. a) Macrophages were infected with VSV-G-pseudotyped 
viruses as indicated. Infected cells were washed and cultured in fresh media. For the next 
24 h, MIP-1β production in supernatants was monitored at indicated time points. 
Afterwards, cells were washed again and fresh media was added. b) Infected 
macrophages were cultured in fresh media with (CD40L-stimulated) or without 
(Unstimulated) CD40L stimulation. After 24 h, MIP-1β production in supernatants was 
measured. c) Net MIP-1β production by CD40L stimulation was caculated by subtracting 
the MIP-1β background in unstimulated group from the gross MIP-1β production in 
CD40L-stimulated group. 
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Indeed, it has been described that several events in CD40 signaling pathways might be 
involved in NF-B activation. For example, activation of phosphoinositide 3 kinase 
(PI3K) is one of the early kinase events after CD40 activation. PI3K can activate IκB 
kinase (IKK) that phosphorylates IB to mediate NF-B activation. CD40 activation is 
also coupled with activation of the ERK signaling pathway (274).  PI3K and ERK 
signaling pathways are both important for NF-B activation in monocytic cells (275). In 
addition, regions of CD40 which interact with different intracellular TRAF members 
have been identified. Among the TRAF proteins, TRAF2, TRAF5 and TRAF6 are able to 
activate signaling pathways of NF-B activation by inducing IKK activation. Thus, the 
interaction between CD40 and TRAFs adds to more complexity of CD40-induced NF-B 
activation. Although some evidence suggests Nef may intersect the CD40 signaling 
pathway in HIV-1 infected macrophages, it remains to be fully established what stage of 
the CD40 signaling pathways is hijacked by Nef. To this end, future experiments by 
genetically or chemically inhibiting certain cell signaling pathways in macrophages might 
be helpful. In addition, the identification of the KEK motif offers a functionally defective 
mutant that we can utilize to eventually clarify the specific pathways that are regulated by 
Nef.  
 
 
 
 
 
110 
 
2.3. The role of the KEK motif  
Technically, delivery of Nef into macrophages can be provided by extracellular rNef or 
endogenous Nef expression through viral transduction using Adeno, M-tropic HIV-1 
ADA or VSV-G-pseudotyped viral systems (1, 197, 198). Nevertheless, Nef seems to 
induce similar effects in macrophages no matter how it is delivered. Consistently, Nef-
dependent MIP-1β induction has been confirmed in all the systems with a common 
finding that myristoylation of Nef is not strictly required. Therefore, it is possible that 
Nef may not have to be targeted to the cell membrane to be functional, and an abundant 
pool of cytoplasmic Nef proteins may be sufficient to trigger signals for gene activation. 
It has been shown that extracellular rNef can be efficiently internalized by macrophages 
and two motifs D173D and E154E are required for the subsequent NF-B activation (197). 
In contrast, these motifs seem to be largely dispensable for MIP-1β induction by de novo 
synthesized Nef during HIV-1 infection in macrophages (Fig. 4-8). Since these two 
motifs seem to be more involved in Nef trafficking via the endocytotic machinery (88, 
276), MIP-1β induction by the extracellular rNef may need transportation of internalized 
rNef to specific intracellular compartments to be functional for subsequent gene 
activation. Clearly, mutations in the DD, EE have been shown to impair Nef-induced 
CD4 down-regulation (87, 88).  Compared to the DD, EE motifs, the KEK motif should 
represent a more essential feature of Nef for signal transduction. Since mutagenesis in 
this motif does not affect general activities of Nef such as CD4 and MHC-I down-
regulation, we do not expect mutations in this motif to alter the subcellular distribution of 
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Nef in macrophages. Instead, the functional losses of the K92EK/3A mutant may reflect a 
subtle but important event that is regulated by Nef. Remarkably, this motif is highly 
conserved in Nef alleles from different HIV-1, SIV and HIV-2 clades, which indicates a 
strong evolutionary pressure for primate lentiviruses to maintain this functional motif. 
However, futher experiments should be done to determine whether mutations in the KEK 
motif can be quickly reverted after passage in macrophages or in SIV-infected monkey 
models.  
At present, the exact role of the KEK motif is unclear. We did one experiment to 
determine the contribution of each residue within the K92EK motif by individually 
substituting K92, E93 or K94 for alanine and evaluating the impact on chemokine 
induction in infected macrophage. While K92 was largely dispensable for Nef-dependent 
induction of MIP-1 in infected macrophages, E93 and K94 were necessary for the 
induction of MIP-1 by HIV-1 Nef (Fig. 5-4). Therefore, among the residues of K92EK 
motif, residues E93 and K94 seem to make the most contribution to chemokine induction. 
Since this charged motif is structurally exposed with full surface accessibility, K92EK 
may lie in the region of HIV-1 Nef that interfaces with cellular factors. The carboxylate 
side chains of these residues may protrude and form hydrogen bonds with a potential 
binding partner. In fact, a similar model has been established in T cells where Nef forms 
a complex with Pak-2 and others cellular factors that initiate downstream signaling events 
to regulate cell activation (136, 146). While this may similarly occur in infected 
macrophages, it seems unlikely that the loss of two residues E93 and K94 could 
completely destabilize such interactions. Althought we identified the KEK motif by  
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Figure 5-4: Role of individual Nef K92EK residues in MIP-1β induction. 
Macrophages were infected with viruses expressing wild-type HIV-1 Nef or Nef mutants 
harboring individual alanine substitutions within the KEK domain. Left panel, viral 
replication was determined by RT activity. Right panel, MIP-1β production was 
measured by ELISA. 
 
 
 
 
 
 
 
 
 
 
113 
 
selectively examining several conserved candidates within the 31 amino acid region, a 
complete alanine scanning throughout the region might reveal more information 
regarding other necessary motifs. This will improve our understanding of the KEK motif 
possibly as a team member in cellular regulation by Nef.  
Moreover, the glutamate and lysine residues in this motif might have some indications. 
Although Nef has the ability to bind several kinases, so far there is no evidence to support 
any kinase activity of Nef itself and we have found no obvious similarities for the KEK 
motif to any known kinase domains. However, it is possible that Nef may interact with a 
cellular kinase to trigger the signaling pathway. The glutamate residue may be important 
for such interaction, since glutamate-based motifs have been previously shown to play an 
important role in Nef’s interaction with cellular partners (88, 93, 96). Further 
mutagenesis analysis with E93/D and E93/Q mutants will address the importance of the 
side chain and the negative charge of the E93 residue. In addition, the lysine residue is a 
good position for ubiquitination modification. Indeed, among the 10 lysines residues of 
Nef, ubiquitination of K92 and K94 has been confirmed (89).  Presumably, poly-
ubiquitination of Nef may lead to different physiological results depending on the type of 
poly-ubiquitin chains. Nef may form a complex with an inhibitory factor for a certain 
signaling pathway and ubiquitination mediated by K48 linkage could be a degradation 
signal to remove the inhibition. Recently, more focus has switched to the regulatory 
effect of K63 ubiquitination (277). Some evidence has linked K63 ubiquitination of 
TRAFs to CD40-induced NF-κB activation (278). If Nef does indeed mimick a CD40 
signaling pathway in infected macrophages, it is possible that Nef triggers NF-κB 
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activation the same way as TRAFs through regulatory ubiquitination. Nevertheless, 
future experiments should be performed to test these possibilities in order to fully 
understand the exact role of the KEK motif.  
2.4 A proposed model  
It has been established in T cells that expression of Nef triggers a transcriptional program 
that shares 97% similarity to that induced by anti-CD3 T cell stimulation (279). Our 
studies support a similar idea that Nef manipulates cell signaling pathways in 
macrophages.  The direct result of dysregulated macrophage activation is the release of a 
wide range of cellular factors; these include not only chemokines/cytokines such as MIP-
1, MIP-1, IL6, IL-16 but also large molecules such as ferrin and even factors that are 
neurotoxic. These molecules cause various effects on bystander cells; T cells are 
recruited and activated to better support viral replication. B cells are hyperactivated and 
thus dysfunctional. Neuronal cells are exposed to neurotoxins and suffer from apoptosis. 
All these contribute to a model in which Nef alters cellular conditions of macrophages 
that promote viral dissemination and lead to pathogenesis. Our studies indicate the KEK 
motif of Nef as the molecular basis for this model. This paves the way for future studies 
to explore machanisms behind the model. 
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3. Future directions  
Identification of the KEK motif is just a start of another Nef story in which many blanks 
are to be filled. What is the exact molecular mechanism of Nef regulation in macrophages? 
How does the KEK motif fit in this model? Which signaling pathways are involved? Is 
the KEK motif also important in regulation of other cells such as T cells, B cells, DCs? 
How and to what extent does the KEK motif affect other Nef functions in vitro? How do 
these effects contribute to the totality of Nef function in vivo? 
Among all the questions we may have, two seem to be of higher priority. Firstly, the 
biological significance of the KEK motif should be evaluated in vivo. The importance of 
the KEK motif can be further analyzed in transgenic mouse models and the SIV/macaque 
model of HIV-1 infection. Such experiments should determine the selective pressure of 
the KEK motif after passage as well as the impact of the KEK motif on viral fitness and 
pathogenicity in vivo. On the molecular basis, future studies should identify the cellular 
factors that may be regulated by Nef via the KEK motif. This will be the key to a better 
understanding of the exact molecular mechanisms. To this end, we have got some 
interesting preliminary results in our pilot co-immunoprecipitation experiments. We 
repeatedly observed a ~70kDa band in the co-immunoprecipitates with the wild-type Nef 
but not with a Nef mutant lacking the KEK motif (Fig. 5-5). Although the identity of this 
band remains to be confirmed, the existence of such potential factors may guide us to the 
next page of the KEK story of Nef.   
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Figure 5-5: A 70-kDa protein co-precipitates with Nef but not with the ΔKEK 
mutant. Anti-HA immunoprecipitates from 293T cells transiently expressing Nef-HF, 
dKEK-HF or Vpx-HF were analyzed by SDS/PAGE and silver staining.  
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